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1. Abbreviations  
 
         AfCalAp                   Aspergillus fumigatus extracellular thaumatin domain protein 
         AFAlp                      Aspergillus fumigatus extracellular alkaline proteinase  
         AfD                          Aspergillus fumigatus diffusible product  
         aHUS                       atypical hemolytic-uremic syndrome 
         Als                           Agglutinin-like sequence  
         AMD                        Age related macular degeneration 
         AP                            Alternative pathway  
         APC                         Antigen presenting cell 
         Bac                           β-protein 
         C1-INH                    C1 inhibitor  
         C4BP                       C4b-binding protein  
         ca.                            circa  
         CFHRs                     Complement Factor H related proteins 
         CHIPS                      Chemotaxis inhibitory protein of Staphylococcus aureus 
         CR1                          Complement receptor 1 
         CR2                          Complement receptor 2 
         CR3                          Complement receptor 3 
         CR4                          Complement receptor 4 
         CP                            Classical pathway  
         CRASPs                   Complement regulator acquiring surface proteins 
         CRP                         C-reactive protein 
         CCP                         Complement control protein      
         CTL                         Cytotoxic T lymphocyte 
         DAF                         Decay accelerating factor  
         DNA                        Deoxyribonucleic acid 
         DiO                          3, 3'-dioctadecyloxacarbocyanine perchlorate 
         EACAM1                Carcinoembryonic antigen-related cellular adhesion molecule 1 
         Ecb                           Extracellular complement-binding protein 
         ECM                        Extracellular matrix 
         EED1                       Epithelial escape and dissemination 1 
         Efb                           Extracellular fibrinogen-binding protein 
         Ehp                           Efb homologous protein 
         ELISA                      Enzyme-linked immunosorbent assay 
         ∆Factor B-HS           Factor B depleted human serum 
         ∆Factor H-HS          Factor H depleted human serum  
         FB                            Factor B       
         Fba                           Fibrinogen binding protein 
         FD                            Factor D  
         FHA                         Filamentous hemagglutinin 
         fHbp                         factor H-binding protein               
         FHL-1                      Factor H like protein 1 
         FP                            Factor P       
         PKH1                       Forkhead transcription factor 1 
         gC                            Glycoprotein C 
         GFP                          Green fluorescence protein  
         GNA 1870               Genome-derived neisserial antigen 1870 
         gpA                          Glycoprotein A 








         HaCaT                      Human adult low calcium temperature keratinocyte 
         HcpA                        Human complement regulator and plasminogen binding protein A   
         Hgc1                         Hypha-specific G1 cyclin-related protein 1 
         Hic                            Factor H-binding inhibitor of complement    
         HIV                          Human immunodeficiency virus 
         HRP                         Horseradish peroxidase   
         Hsf                           Haemophilus surface fibril 
         HUVEC                   human umbilical vein endothelial cell 
         Hwp1                       Hyphal cell wall protein 1 
         HYR1                       Hyphally regulated cell wall protein 1 
         iC3b                         inactive C3b 
         IFN-γ                        Interferon gamma 
         Int1                           Integrin-like protein 1 
         kDa                           kilodalton 
         LcrV                         Virulence V-antigen 
         Len                           Leptospiral endostatin-like protein 
         LfhA                         Leptospira factor H-binding protein A 
         Lip                            Lipase 
         LP                             Lectin pathway  
         LSM                         Laser scanning microscopy 
         MAb                         Monoclonal antibody  
         MASP                      Mannose binding lectin associated protease 
         MBL                         Mannose binding lectin 
         MCP                         Membrane cofactor protein 
         MFI                          Median fluorescence intensity  
         mg                            milligram  
         MHC                        Major histocompatibility complex 
         µg                             micro gram 
         µl                              micro liter  
         ml                             milli liter  
         MPGN                      Membranoproliferative glomerulonephritis 
         NHS                         Normal human serum  
         NK cell                     Natural killer cell   
         NO                            Nitric oxide  
         NS1                          Nonstructural protein 1 
         Omp                         Outer membrane protein 
         OPA protein             Opacity-associated protein  
         OPD                         o-phenylenediamine dihydrochloride 
         PaAP                        Alkalinprotease from Pseudomonas aeruginosa        
         PaE                           Elastase from Pseudomonas aeruginosa  
         PCR                          Polymerase chain reaction   
         PspC                         Pneumococcal surface protein C 
         Phr1                          pH regulated protein 1  
         Phr2                          pH regulated protein 2 
         Plb                            Phospholipase B 
         PMNs                       Polymorphonuclear leukocytes 
         Por1                          Porin protein 1 
         Pra1                          pH-regulated antigen 1  
         PrtH                          Porphyromonas spp. protease 
         ROS                          Reactive oxygen species 








         Saps                          Secreted aspartic proteinases 
         Sbi                            Staphylococcal binder of immunoglobulins 
         SCIN                        Staphylococcal complement inhibitor 
         Scl                            Streptococcal collagen-like protein  
         ScpB                        Streptococcal C5a peptidase (ScpB) of Group B streptococci 
         SCR                          Short consensus repeat domain 
         SIC                           Streptococcal inhibitor of complement 
         sTCC                        soluble TCC 
         Stx2                          Shiga toxin 2 
         TC cell                      T cytotoxic cell 
         TCC                          Terminal complement complex 
         TCR                          T cell receptor         
         TEF1                         Transcription elongation factor 1 
         TH cell                      T helper cell 
         TLRs                        Toll like receptors             
         TP                             Terminal pathway  
         tPA                           Tissue plasminogen activator  
         Tuf                            Transcription elongation factor 
         uPA                           urokinase-type plasminogen activator 
         UspA                        Ubiquitous surface protein A 
         VacA                        Vacuolating cytotoxin A 



























2. Introduction  
 
Hosts live in a close association with a great variety of infectious microbes, i.e. fungi, bacteria, 
viruses, protozoa and multi-cellular parasites. Therefore, host and microbe interaction happens 
every second within our lives. This interaction is complex and dynamic, and plays a key role 
for pathogenesis. The outcome of such an interaction may range from elimination of microbes, 
to infections caused by microbial pathogens 1 (Figure 1). Upon the course of infection, hosts 
utilize both physical barriers and an efficient immune defense system which includes the 
innate immunity and the adaptive immunity for protection. However, pathogens have evolved 
sophisticated infection strategies to cross tissue barriers, control and evade host immune attack. 
Thus, there is a balance between protective immunity and microbial infection 2. At the end, 
who will succeed depends on the ability of the host to combat microbial infection and the 
ability of microbial pathogens to evade host immune defenses. How the host immune system 
is activated and regulated to eliminate any invading microbe and maintain cellular homeostasis, 
and how pathogens establish an infection will be explained in the following. 









Figure 1. Balance of the protective immunity and microbial infection. Hosts utilize both tissue barriers and 
efficient immune responses, e.g. inflammation, phagocytosis, killing, complement mediated cell lysis and 
adaptive immunity for protection. Pathogens evolved different virulence factors and sophisticated evasion 
strategies for infection. The graphic was modulated from Denise M. Monack, et al. Nature Reviews Microbiology. 
Sep. 2004. 
 
2.1 Overview of the host immune responses 
 
The physiological function of the host immune system is to defense against infectious 
microbes. Broadly speaking, the protective host immune responses can be classified into two 
major categories: innate immunity and adaptive immunity. Both types are further divided into 
humoral and cellular immune responses, which are mediated by different proteins or cell types 
(Figure 2).  
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    Figure 2. Classification of host immune responses and corresponding components 
 
The innate immune system provides an early defense line that blocks the entry of the microbes, 
limits the growth of many infectious microbes that invade host tissues, and eliminates any 
harmful host cell 3,4. The first interaction sites between individual microbial pathogens and 
their hosts are mainly the skin, gastrointestinal and respiratory tracts. These contact sites are 
lined by continuous epithelial cells that serve as barriers to prevent the entry of microbes from 
the external environment. If successfully crossing these epithelial barriers, microbial 
pathogens are immediately attacked by the next step of innate immune response, which is 
mainly mediated by complement system, neutrophils, macrophages and other leukocytes 5. 
During this process, complement is fully activated and promotes destruction of the microbes 
and inflammation. In addition to complement activation, local resident phagocytes release 
cytokines and chemokines. These released immune effector molecules together with 
complement based C5a and C3a function as the “messenger molecules” to recruit neutrophils 
and macrophages to sites of infection. These activated leukocytes phagocytose and kill 
microbes, further release cytokines to recruit and activate more host leukocytes to infection 
sites. All these fast responses happen within seconds after infection until hours in most cases 
and efficiently control and eradicate many infectious microbes. In contrast to the fast innate 
immunity, adaptive immunity starts to function at the later stage after days of the infection 
(Figure 3). The adaptive immunity, which is specific, can distinguish between different, even 
close related microbes and molecules. The adaptive immunity utilize three main strategies to 
combat microbes: (i) secretion of antigen specific antibodies that bind to microbial antigens; 
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(ii) phagocytosis and killing of ingested microbes; and (iii) direct destruction of the microbe-



















Figure 3. Overview of host innate and adaptive immune responses and corresponding cells. The innate 
immunity is composed of epithelial barriers, complement and immune cells (such as macrophages, neutrophils, 
dentritic cells and NK cells). The innate immunity provides fast and initial defense against infection. The 
adaptive immunity is initiated after days of infection, which developed by recognition, activation and effect 




2.2 Innate immunity 
 
The innate immunity is the early defense line against infections agents. It is activated by the 
structures that are characteristic of microbes, but not available on mammalian cells. These 
conserved structures are called pathogen associated molecular patterns (PAMPs), such as 
lipopolysaccharides, teichoic acids and mannose-rich oligosaccharides. The receptors that bind 
PAMPs are called pattern recognition receptors (PRRs), including toll like receptors (TLRs), 
pentraxins, dectin-1 and ficolins. The principle components of the innate immunity are: (i) 
physical and chemical barriers, such as epithelia and anti-microbial substances produced at 
epithelial surfaces; (ii) the complement system as well as other inflammation mediators in the 
serum; (iii) macrophages, granulocytes (such as neutrophils, eosinophils and basophiles), mast 
cells, dendritic cells and natural killer cells (NK cells); and (iv) cytokines and chemokines that 
regulate and coordinate many activities of host innate immune responses 7. Upon infection, 
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innate immunity uses two major effective systems to recognize and eliminate foreign and 
dangerous cells: the complement system and the cellular immune response. 
 
2.2.1 Complement system 
The term “complement” was originally applied by Paul Ehrlich to describe the activity of lysis 
of bacteria in an antibody containing serum. Later this lytic activity was further identified as a 
heat-labile serum component mainly by Bordet 8. Complement contains more than 30 soluble 
and membrane bound proteins. Complement forms the first defense line of the innate 
immunity, and is distributed in plasma, body fluid, extra-cellular matrices, and also on the host 
cell surfaces 9,10. Complement can be activated by three different pathways within seconds 
upon infections: (i) the alternative pathway, (ii) the lectin pathway; and (iii) the classical 
pathway. All three pathways end with a terminal pathway cascade (Figure 4). Complement 
activation leads to the rapid destruction of a wide range of invading microbes by direct lysis or 
promotion of phagocytosis and inflammation. The complement based biological effects play a 
central role in the innate immune defense. The complement system directs its activity 
specifically to the surface of invading microbes and injured cells. However, intact host cells 
which express endogenous complement regulators at the surfaces, or recruit fluid phase 
complement regulators to the surfaces are protected from complement attack. These regulators 
keep the whole complement activation under control and protect hosts against complement 
attack.  
 
2.2.1.1 Complement activation  
 
The alternative pathway  
The alternative pathway represents a central immuno-surveillance system. The alternative 
complement activation is initiated in a rapid, spontaneous and antibody independent manner 11. 
The key component of the alternative pathway is C3 which is a 185 kDa large molecule with a 
concentration of 1~2 mg/ml in serum. The first step of the alternative complement pathway 
activation is a spontaneous hydrolysis of the internal thioester bond of C3 by a “tick-over” 
process. Approximately less than 0.5% of C3 are spontaneously and continuously converted 
into a hydrolyzed form C3(H2O), which has many characteristics of C3b 12. C3(H2O) binds 
Factor B in solution and forms a C3(H2O)-Factor B complex, which is then converted into 
C3(H2O)Bb and Ba by Factor D. The newly formed complex C3(H2O)Bb represents the initial 







C3a and C3b. The newly generated C3b covalently bind to the nearby surfaces via the 
thioester bond. This initial surface attached C3b recruits Factor B in the presence of Mg2+, 
which is again cleaved by Factor D. The formed complex C3bBb is the alternative C3 
convertase. Factor P in plasma binds to and stabilizes this C3bBb complex, thereby extending 
the lifetime of the active C3 convertase. The C3 convertase cleaves additional C3 into C3b and 
C3a. In this process, the cleavage products C3b expose an unstable, internal thioester bond 
based on the conformational change, which provides a nascent binding site within C3b for 
interaction with adjacent nucleophils (Figure 4). These surface attached C3b fulfill several 
functions: (i) formation of new C3 convertases and induction of a positive amplification loop 
of the alternative pathway complement cascade; (ii) binding to C3bBb to form a C3bBbC3b 
complex, which represents a C5 convertase, thereby initiating the terminal complement 
pathway and generating C5a; and (iii) opsonization onto the cell surfaces and promotion the 
further adhesion and phagocytosis by human phagocytes.  
 
The lectin pathway  
The lectin pathway is another antibody-independent route for complement activation, which is 
initiated by binding of the mannose binding lectin (MBL) or serum ficolins to oligosaccharides 
at microorganisms surfaces, apoptotic as well as necrotic cells 14-16 (Figure 4). MBLs and 
ficolins have structural similarity to C1. Both have globular binding regions that are associated 
with two serine proteases, named mannose binding lectin associated protease 1 (MASP1) and 
MASP2. These proteases are homologous with C1s and C1r molecules of the classical 
pathway 15,17. MBL binding to a surface induces MASP1 to cleave MASP2. Such activated 
MASP2 cleaves C4 into C4b and C4a 18,19. C4b attaches to a surface and couples C2, which is 
then cleaved by MASP2 into C2b and C2a. Finally a C3 convertase (C4bC2b) is formed, 
which will cleave the central component C3 into C3b and C3a. The newly generated C3b is 
further used for different purpose as described for the alternative pathway.  
 
The classical pathway   
The classical complement pathway activation is mainly initiated by binding of C1q to antigen-
bound IgG or IgM and also to other activating structures, such as markers of damage cells, 
pentraxins and bacterial lipopolysaccharide 20-23. C1 is a large hetero oligomeric complex with 
a molecular weight of approximately 800 kDa. This large complex is composed of single C1q 
molecule and two C1s and two C1r molecules. The intact C1q molecule consists of three 







immunoglobulin receptor site, N-terminal collagen like sequences and the connected triple 
helix. These molecules of C1 are associated noncovalently in a Ca2+-dependent manner 24. 
Binding of the globular head C1q to different activating structures (for example, to IgG in 
immune complexes) induces a conformational change of the C1 complex. This triggers the 
activation of one enzymatic part of the C1 complex, C1r, which then cleaves the other two C1s 
molecules into the active serine esterase 25. The active C1s cleaves the thioester-containing 
protein C4 into C4b and C4a. C4b is immediately attached to nucleophilic amine hydroxyle 
group at nearby surfaces. Actually, only about 10% of active C4b binds to the proteins or 
carbohydrates, the remaining molecules are bound to adjacent water, and form iC4b, which is 
then rapidly catabolized. Surface attached C4b recruits a zymogen C2. When combined with 
C4b, C2 becomes a substrate for C1s and is then cleaved into C2b and the small molecule C2a. 
The newly originated complex C4bC2b represents the classical pathway C3 convertase, which 
cleaves the central component C3 into C3b and C3a. The newly formed C3b is either 
integrated into the alternative complement pathway which induces an amplification loop of 
complement activity, or deposits onto the surfaces and mediates phagocytosis, or couples onto 
the C3 convertases to form C5 convertases and initiates the terminal complement pathway 
(Figure 4).   
 
The terminal complement pathway  
Following the activation, all three complement pathways merge at the central step, the 
cleavage of C3 into C3b and C3a. When newly generated C3b molecules are coupled with the 
C3 convertases (C3bBb or C4bC2b), C5 covertases are therefore generated. The newly 
generated C5 convertases further cleave C5 into C5a and C5b, which is the first step toward 
the terminal complement pathway (TP) 26. The newly generated C5b is attached to C3b within 
the C5 convertases, binds C6 and forms a C5bC6 complex. Binding of C6 to C5b stabilizes the 
membrane binding site in C5b and exposes a binding site for C7. Binding of C7 to C5bC6 
induces the transition of a hydrophilic to a hydrophobic state that allows the C5bC6C7 
complex to bind tightly to the lipid bi-layers. Subsequently, C8 is coupled to the former 
complex, then followed by a polymeric complex of up to fourteen C9 monomers to form a 
terminal complement complex (TCC) 27,28. TCC is therefore leads to the lysis of Gram negative 
bacteria or damaged host cells 29 (Figure 4). TCC is suggested to show additional different 































Figure 4. Complement activation pathways. Complement is activated by the alternative, lectin and classical 
pathways. Each pathway creates a C3 convertase which cleaves the central complement component C3 into C3a 
and C3b. C3b attached to nearby surfaces can be used for: (i) initiation of an amplification loop of the 
complement cascade via the alternative pathway; (ii) opsonization of surfaces for phagocytosis; and (iii) binding 
to the C3 convertases, which form C5 convertases. C5 convertases cleave C5 into C5a and C5b. C5b binds C6 
and C7, followed with C8 and C9 to form the TCC. C3a and C5a initiate and amplify inflammation. Complement 
activation is highly regulated by complement regulators to protect host cells from complement attack. Alternative 
pathway activation is mainly regulated by the soluble complement inhibitors Factor H and FHL-1, whereas the 
classical and lectin pathway are mainly controlled by C1 inhibitor (C1-INH) and C4BP. C5 convertases and 
terminal complement pathway are controlled by CFHR1, vitronectin and clusterin. FB, Factor B. FD, Factor D. 
FP, Factor P. 
 
 
2.2.1.2 Biological effects of the complement system 
The complement system is an effective part of the innate immunity. This protein-based 
defense system serves multiple functions, such as: (i) initiation and amplification of an 
inflammation; (ii) induction or mediation of phagocytosis; (iii) elimination of the invaded 
microbes or clearance of the debris from tissues to maintain tissue homeostasis; and (iv) a link 
between the innate and adaptive immunity 9,10. All these effector functions are based on newly 
generated cleavage products upon the activation of the complement system, such as C3a, C5a, 
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C3a and C5a, known as anaphylatoxins are generated and released into the fluid phase upon 
C3 and C5 cleavage by convertases. C3a and C5a bind to specific receptors, i.e. the C3a 
receptor, the C5a receptor and the C5a like receptor 2. Via ligation, C3a and C5a mediate 
leukocyte chemotaxis, adhesion of leukocytes to vascular endothelium, degranulations of the 
mast cells, contractions of the smooth muscles, increasement of vascular permeability, and an 
aggregation of platelets and leukocytes 32. Recent findings suggest that C3a and C5a do also 
regulate cell apoptosis, lipid metabolism, recruit and activate antigen-presenting cells and T 
cells 33. Furthermore, C3a displays an anti-microbial activity 34,35 (Figure 5). 
 
C3b, C4b and the further degradation products iC3b or C3dg, which deposit onto target cells, 
are recognized by specific receptors, like complement receptor type 1 (CR1, also named 
CD35), CR2 (CD21), CR3 (CD11b/CD18), CR4 (CD11c/CD18) that are expressed at different 
host cell surfaces (Table 1) 8. The specific ligand-receptor interaction facilitates many 
biological effects. For example, binding of C3b or C4b to CR1 mediates endocytosis and 
phagocytosis of target cells by phagocytes and also mediates the transport of immune 
complexes to the liver for clearance. This complement dependent clearance of immune 
complexes prevents the chronic inflammation and complex deposition in blood vessels 36. 
Moreover, CR1 binds C3b tagged immune complexes and subsequently inhibits B-cells to 
secrete antibodies, which is important for the down regulation of a B-cell response and 
blockade of auto antibody release 37. In addition, binding of iC3b or C3dg to CR2 results in B 
cell activation and further induction of the adaptive immunity 38. Binding of iC3b to CR3 
efficiently mediates phagocytosis of opsonized microbes or particles  by host phagocytes 39,40 
(Figure 5). These complement dependent biological function lead to efficient elimination of 
any invading microbe and maintain host cellular homeostasis.   
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TCC, which is formed during the final phase of the complement activation cascade, mediates 
the lysis of the targeted cells and particles, like Gram negative bacteria and other foreign 
cells 29. However, in recent years, it was reported that soluble TCC (sTCC) also induces 
cytokine release by endothelial cells. Based on the cytokine release, sTCC indirectly mediates 
adhesion and transendothelial migration of polymorphonuclear leukocytes (PMNs) 30. In 
addition, TCC is suggested to induce phagocytosis of microbes by PMNs via depositing on the 













Figure 5. Complement based biological effects. The complement based biological effects are mediated by 
different cleavage products generated upon complement activation. 
 
2.2.1.3 Complement regulation  
Complement system is a very powerful protein-based defense system with potent pro-
inflammatory effects. Uncontrolled complement activation can cause severe damage on 
autologous cells and tissues. Complement regulators protect host cells and extra-cellular 
matrices from complement attack and switch off the self amplifying cascade. These regulators 
are distinguished into plasma proteins and membrane bound proteins. Both types belong to the 
members of the complement activation regulator gene clusters. These regulators control 
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Fluid phase regulators  
The Factor H protein family comprises eight homologous plasma proteins: Factor H, Factor 
H splicing variant Factor H like protein 1 (FHL-1), and the complement Factor H related 
proteins (CFHR1-CFHR5) (Figure 6). The individual complement Factor H family protein 
shares common features, and each is composed of single structural elements termed short 
consensus repeat domains (SCRs). All members of the Factor H protein family are primarily 
produced in the liver. Factor H and FHL-1 are two major regulators of the alternative 
complement pathway that act both in fluid phase and on cell surfaces. Factor H is a 150 kDa 
plasma protein with a concentration of 350~600 µg/ml. Factor H is a single polypeptide, 
consisting of 20 SCRs (Figure 6). Each SCR has approximately 60 amino acids with four 
conserved cysteine residues which are responsible for initiating a globular domain folding 41,42. 
FHL-1 is a splicing variant of Factor H, which is composed of the identical N-terminal 
SCRs1-7 of Factor H and four additional unique C-terminal amino acids. The plasma 
concentration of FHL-1 is approximately 50 µg/ml. Both regulators have three major functions: 
(i) cofactor activity for the plasma protease Factor I mediated C3b inactivation; (ii) inhibition 
on the alternative pathway C3 convertase assembly; and (iii) decay accelerating activity on the 
C3 convertase. All these regulatory functions of Factor H and FHL-1 are performed by the N-
terminal SCRs1-4. Via binding to the regulatory region of Factor H, C3b is able to expose its 
cleavage site for Factor I. The α-chain of C3b is then cleaved by Factor I into the inactive C3b 
(iC3b) and C3f. This step controls or interrupts the complement cascade 43. In addition, 
SCRs1-4 compete with Factor B for C3b binding, which inhibits C3 convertase assembly and 
accelerates the decay of an assembled C3 convertase. Factor H protects host cells against the 
alternative pathway complement attack by binding to cell surfaces. In addition to the 
regulatory regions, Factor H also contains multiple other ligand binding and functional regions, 
which are located either in the middle region or in the C-terminus. Single SCR7 domain binds 
heparin and CRP. SCRs8-11 represent the second CRP binding region 44 and SCRs12-15 are 
the second C3b binding sites. The C-terminal SCRs18-20 contain the binding regions for host 
surfaces, C3b and heparin (Figure 6) 43,45. Recently, SCRs19-20 were identified as a new CRP 
binding region 46. Mutations in the binding and functional regions of Factor H have severe 
effects on hosts and are associated with several diseases. For example, a mutation within the 
regulation domains (SCRs1-4) leads to the autoimmune disease, like membranoproliferative 
glomerulonephritis II (MPGN) because of the uncontrolled complement activity in the body 47. 
A single amino acid polymorphism mutation in SCR7 is associated with age related macular 







atypical hemolytic-uremic syndrome (aHUS), which is due to the impaired complement 














Figure 6. Domain structures of the Factor H protein family. Factor H protein family contains Factor H, FHL-
1 and CFHR1-CFHR5. Factor H is composed of 20 SCRs. Each SCR contains approximately 60 amino acids. 
FHL-1 contains seven SCRs which are identical to the N-terminus of Factor H and four extra amino acids. 
CFHR1 contains five SCRs, which have different sequence homologous identities with Factor H. Factor H and 
FHL-1 are complement regulators of the alternative complement pathway. Both regulators have multiple binding 




C1 inhibitor and C4b-binding protein are two fluid phase complement regulators that 
control the classical and the lectin pathway. C1 inhibitor (C1-INH) is a serine protease 
inhibitor that binds activated C1 and removes C1r and C1s from the complex, thereby 
inhibiting the enzymatic activity to cleave C4. Similarly, C1-INH also blocks the activation of 
MASPs. Thus, C1-INH disables the first step of the classical and lectin pathway complement 
activation 53. 
 
C4b-binding protein (C4BP) controls the later stages of the classical and lectin pathway. 
C4BP is a heptameric plasma regulator with a “spider-like” configuration. C4BP is a 570 kDa 
plasma glycoprotein, with a serum concentration of ca. 250 mg/l. The major form of C4BP 
consists of seven identical α-chains (70 kDa) and one single β-chain (45 kDa) 54. Each α-chain 
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contains eight SCRs, while β-chain contains three SCRs (Figure 7). C4BP binds C4b via 
SCRs1-2 and binds heparin via SCRs1-3. By binding to C4b, C4BP makes C4b accessible for 
Factor I cleavage and inactivation. Furthermore, C4BP enhances the decay of the classical and 
lectin pathway C3 convertase 55. C4BP also has low cofactor activity for cleavage of C3b and 
a low decay accelerating activity on the alternative pathway C3 convertase 56.  
                                
β chain





Figure 7. Domain structures of C4BP. C4BP contains seven identical α-chains (each has eight SCRs) and one 
single β-chain (three SCRs). C4b binding domains are located between SCR1 and SCR2, while heparin binding 
sites are SCRs1-3. 
 
Complement Factor H related protein 1 (CFHR1) is a newly described soluble regulator of 
the terminal complement pathway 57. CFHR1 is present in plasma as two different 
glycosylated forms (CFHR1α and CFHR1β). CFHR1 contains five SCRs (Figure 6). The C-
terminal SCRs3-5 show high identity to SCRs18-20 of Factor H. Consequently, CFHR1 
competes with Factor H for binding to cell surfaces. In contrast to Factor H, CFHR1 inhibits 
two steps of the terminal pathway cascade: (i) blocking the cleavage of C5 into C5b and 
anaphylatoxin C5a by alternative C5 convertase; and (ii) inhibition of binding of C7 to C5bC6, 
thereby blocking TCC formation. 
 
Vitronectin and clusterin are two soluble regulators of the terminal complement pathway. 
Vitronectin exists in the plasma either as a single chain (75 kDa) or as a truncated form of 
65 kDa and 10 kDa. Vitronectin inhibits the insertion of C5b-C7 complex into the cell 
membranes by binding to its membrane binding sites, thereby blocking the cell lysis 58. In 
addition, vitronectin blocks the tubular formation by binding to TCC 59. Clusterin is a 
70~80 kDa glycoprotein, which binds the C5b-C7 and C5b-C8 complexes and prevents 








Membrane bound regulators 
In contrast to the fluid phase inhibitors, there are also membrane bound regulators, like decay 
accelerating factor (DAF/CD55), membrane cofactor protein (MCP/CD46), and membrane 
glycoprotein complement receptor 1 (CR1/CD35). DAF is expressed on vascular endothelial 
cells, erythrocytes, epithelial cells, lymphocytes and also on epithelial cells of the placental 
trophoblast. As a membrane regulator, DAF dissociates both C3 and C5 convertases of all 
three activation pathways. MCP is expressed on many kinds of cell types including epithelial 
and endothelial cells, fibroblasts, spermatozoa and placental trophoblasts and also circulating 
nucleated cells, but not erythrocytes. MCP is a cofactor for Factor I mediated inactivation of 
C3b and C4b. CR1 is expressed on circulating cells including erythrocytes. CR1 inhibits the 
assembly of the classical and alternative C3 convertases and also acts as a cofactor for Factor I 
mediated cleavage of C3b and C4b 62. Furthermore, CD59, as a terminal complement pathway 
inhibitor, is a GPI anchored  protein, which is mainly expressed on epithelial, endothelial and 
circulating cells 63. CD59 regulates terminal complement pathway activity by blocking binding 
of C9 to C5b-C8 and C9 polymerization.   
 
2.2.2 Cellular response of innate immunity 
In addition to complement, cellular immune response is another major defense mechanism that 
protects hosts against infectious agents. Once microbial pathogens penetrate or cross the 
epithelial barriers, cellular immune response is initiated due to the recruitment of leukocytes 
like neutrophils, macrophages, dendritic cells and eosinophils to the sites of infection. There 
are three major stages in leukocytes migration: (i) attachment of circulating cells to the 
vascular endothelium by binding to the adhesion molecules; (ii) movement through the 
endothelial cells; and (iii) migration of leukocytes to the sites of infection or inflammation 
after traversing the endothelium 8. This migration process is partially guided by a variety of 
soluble immune effector molecules. These effector molecules, also termed “messenger 
molecules” are cytokines or chemokines which are produced by local resident macrophages, 
endothelial cells and other cell types which is involved in response to microbial products. In 
addition, these effector molecules include anaphylotoxins C3a and C5a generated upon 
complement activation. Neutrophils are the most abundant populations of circulating white 
blood cells. Neutrophils are recruited and attracted at the earliest phase of inflammatory 
response 64. Upon arrival at sites of infection, neutrophils immediately recognize invaded 
microbes via surface expressed PRRs. The PRRs-PAMPs ligation induces the effector 







molecules, like reactive oxygen species (ROS), nitric oxide (NO) and proteolytic enzymes 
within a phagolysosome, thereby killing phagocytosed microbes. In addition, neutrophils 
contribute to collateral tissue damage that occurs during inflammation 65,66.  
 
Following the early recruitment of neutrophils, monocytes migrate from blood into tissues 
where monocytes mature and differentiate to macrophages. Macrophages, similar to 
neutrophils, phagocytose and intracellularly kill microbes. Macrophages are also capable of 
extra-cellular killing of infected or altered self cells. Furthermore, macrophages produce 
growth factors for fibroblasts and endothelial cells that participate in the remodeling of tissues 
after infection and injury. Activated macrophages can also act as antigen-presenting cells, 
which are required for the induction of adaptive immunity 67.  
         
In addition, these activated neutrophils and macrophages release additional cytokines and 
chemokines to recruit more macrophages, neutrophils and other leukocytes to the sites of 
infection. These newly activated leukocytes further phagocytose and kill more infectious 
agents. Thus, this whole defense system is efficiently amplified.  
     
During the course of cellular immune response, many other human cells, such as dendritic 
cells, natural killer (NK) cells , eosinophils, basophils and mast cells also recognize and 
eliminate infectious microbes. For example, dendritic cells are often in contact with the 
external environment. Therefore, these cells are very important in engulfing and presenting 
antigens to cells of the adaptive immune system, therefore serving as a link between the innate 
and adaptive immune system 68. NK cells are stimulated by IL-12 which is released via 
macrophages. The stimulated NK cells function as linage cells related to lymphocytes that 
recognize and direct kill infected or stressed host cells, secret inflammatory cytokines. In 
addition to killing infected cells, NK cells are the main source of Interferon-γ (IFN-γ) which 
activates macrophages to kill ingested microbes 69.  
 
2.3 Adaptive immunity 
 
The adaptive immune system is characteristic of exquisite specificity for distinct antigens and 
ability to remember repeated microbes. It is triggered in vertebrates when a pathogen evades 
the innate immune system and generates a threshold level of antigens. The major functions of 







process of antigen presentation; (ii) generation of responses that are tailored to maximally 
eliminate specific microbes or microbes-infected host cells; and (iii) development of 
immunological memory, in which each microbe is “remembered” by a signature receptor.  
The adaptive immune response involves two groups of cells: lymphocytes and antigen 
presenting cells (APCs). Lymphocytes, a type of white blood cells, are produced in the bone 
marrow during the process of hematopoiesis and residue in various lymphoid organs. 
Lymphocytes are able to recognize newly generated antigens via specific membrane receptors. 
There are two major types of lymphocytes which differ in antigen recognition and functions: B 
lymphocytes and T lymphocytes.  
2.3.1 B lymphocytes  
B cells mature within the bone marrow, circulate in the blood and lymph system, then reside in 
different lymphoid organs. During the maturation, B cells express a unique antigen-binding 
membrane receptor, which are antibodies. When a B cell first encounters an antigen which is 
specific for the membrane bound antibody, the antigen attaches to a receptor. This complex 
therefore stimulates B cells to differentiate into effector cells called plasma cells and memory 
cells. Memory B cells display memory and “remember” that specific antigen. Helper T cells 
(CD4+) help B cells in such differentiation and proliferation process 70. Plasma cells survive 
for a few days and continuously secrete antibodies that are specific to the antigens. This 
process is very efficient as a single plasma cell can secrete approximately 10000 antibodies 
per second. Secreted antibodies are major effector molecules of humoral immunity, which 
combat microbes mainly by: (i) inducing classical complement activation via binding of IgG 
or IgM to microbes; (ii) mediation of phagocytosis by coating the microbes with IgG; and (iii) 
binding and neutralizing the microbes 71. Memory B cells have a longer lifespan and continue 
to express membrane-bound receptor with the same specificity as the original parent cells. 
Whenever encountering the same antigen again, memory B cells rapidly recognize the antigen, 
multiply, change into plasma cells, and produce antibodies. This second exposure makes the 
response quick and more effective.  
  
2.3.2 T lymphocytes  
T cells arise from hematopoietic stem cells in bone marrow and migrate to the thymus to 
mature. During the maturation, T cells express a unique membrane receptor for antigen, called 
T cell receptor (TCR), which is distinguished from the one on other lymphocytes. T cell 







gamma and delta (γδ). These two protein chains are linked by disulfide bonds. TCRs, in 
general, are responsible for recognizing antigens only in association with cell-membrane 
proteins known as major histocompatibility complex (MHC) molecules. T lymphocytes are 
mainly classified into T helper (TH) cells and T cytotoxic (TC) cells, which play a central role 
in cell-mediated immunity. When T cells encounter an antigen that is associated with a MHC 
molecule on a cell surface, T cells proliferate and differentiate into memory T cells and 
various effector T cells. However, effector T cells derived from TH cell (CD4+) and TC cells 
(CD8+) function differently. An effector TH cell secrets various growth factors known as 
lymphokines, which play an important role in activating B cells, TC cells, phagocytes and 
various other cells that participate in immune responses. Under the influence of lymphokines 
secreted by effector TH cells, TC cells are activated into effector cells called cytotoxic T 
lymphocytes (CTLs) via binding to a MHC class I coupled antigen 72. CTL plays a vital 
function in monitoring host cells and eliminating any cells that display foreign antigen on 
MHC-I, such as microbe-infected host cells, tumor cell and cells from a foreign tissue.  
      
Functionally, T helper lymphocytes can be further classified into TH1, TH2 and TH17 which 
secrete different cytokines to facilitate a different type of immune response. For example, TH1 
lymphocytes produce proinflammatory cytokines (such as IFN-γ) which initiate and promote 
an inflammation. However, TH2 lymphocytes produce anti-inflammatory cytokines (such as 
IL-10) which suppress and neutralize an inflammation. Different kinds of cytokines produced 
by Th1 and Th2 cross-regulate each other. Therefore, there is a balance of Th1 and Th2 
responses 73,74. 
       
In addition to TH and TC cells, a regulator T cell is the third type of T cells, formerly known as 
suppressor T cells. Regulator T cells are crucial for maintenance of immunological tolerance. 
Their major role is to shut down T cell-mediated immunity toward the end of an immune 
reaction and to suppress auto-reactive T cells that escaped the process of negative selection in 
thymus 75. 
 
2.4 Epithelial and endothelial cell barriers  
 
An epithelium is a tissue composed of cells that line the cavities and surfaces of structures 
throughout the body. Epithelium is often defined by the expression of the adhesion molecule, 







serve as physical barrier and perform very complex and vital activities to protect the 
underlying tissue and subendothelial matrices from microbial infection, mechanical injury, 
harmful chemicals and excessive water loss 76. As for interfering with the entry of microbes, 
epithelial cells provide a physical barrier, produce anti-microbial peptides and harbor 
intraepithelial lymphocytes that can kill microbes and infected cells. The epithelial barrier is 
considered as an innate immune defense.  
An endothelium is a thin layer of cells that line the interior surface of blood vessels, forming 
an interface between circulating blood and the rest of the vessel wall. Endothelial cells are 
involved in many aspects of vascular biology, including: (i) barrier function; (ii) control of 
blood pressure; (iii) blood clotting; (iv) atherosclerosis; (v) formation of new blood vessels; 
and (vi) inflammation 77. As for the barrier function, the endothelial cells provide a physical 
barrier that separates blood from tissues and prevents pathogenic microbes entering into the 
tissue from the blood stream, thereby protecting hosts from severe systemic infections. The 
endothelial cell barrier also controls the passage of materials and the transit of white blood 
cells into and out of the bloodstream 78. 
2.5 Infection strategies of human pathogenic microbes 
 
Upon spreading and disseminating into a host tissue or target cell, pathogens encounter 
different types of host cells, extra-cellular matrices, tissue fluid and blood which harbor the 
whole host defense system (physical tissue barriers, humoral and cellular immunity). In order 
to survive and overcome host immune surveillances and tissue barriers, pathogenic microbes 
have evolved sophisticated infection strategies, which include two major steps, immune 
evasion and tissue invasion.  
 
2.5.1 Immune evasion 
2.5.1.1 Escaping from complement attack 
Complement forms the first defense line against infectious microbes and is considered as a 
central immuno-surveillance system of innate immunity. Complement evasion by pathogens 
represents a major threat for host immune protection. Strategies utilized by pathogens for 
complement evasion are mainly classified into: (i) acquisition of host complement regulators; 
(ii) expression of endogenous complement inhibitors; and (iii) inactivation of the complement 








Acquisition of host complement regulators is a common strategy used by many microbial 
pathogens for complement evasion. Many pathogens, including fungi, Gram negative and 
Gram positive bacteria, parasites and viruses recruit soluble human complement regulators 
(like Factor H, FHL-1 and C4BP) to their surface via specific surface virulence factors, which 
are called Complement Regulator Acquiring Surface Proteins (CRASPs) 79 (Table 2). 
Attached to pathogen surfaces, these human regulators maintain their inhibitory function and 
block complement activation at the level of the C3 convertases, thereby allowing the pathogen 
to control and evade host complement attack. In addition, some pathogens also utilize terminal 
pathway inhibitors, such as CFHR1, vitronectin and clusterin to block the TCC formation 80 
(Table 2) . Furthermore, the recruitment of complement regulators is not only restricted to 
soluble, but also extended to membrane bound proteins. For example, E. coli and Helicobacter 
pylori utilize CD59 to interfere the TCC formation for terminal complement pathway 
evasion 81,82.  
 
Expression of endogenous complement inhibitors represents a second mechanism used by 
pathogenic microbes to inactive host complement attack. For example, S. aureus expresses 
extra-cellular fibrinogen binding protein (Efb) and its homologous protein (Ehp) that bind C3 
and further inhibit the substrate C3 conversion by the C3 convertases, and also expresses 
SCIN that binds and stabilizes the assembled C3 convertases, thereby interrupting further 
complement progression 83-88. In addition, S. aureus expresses the chemotaxis inhibitory 
protein (CHIPS) that binds and neutralizes the C5a receptor on the surfaces of neutrophils and 
monocytes, thus blocking the anaphylotoxin C5a mediated chemotaxis 89-91. B. burgdorferi 
expresses a CD59-like protein on the surface, which binds C8 and C9, and thus inhibits TCC 
formation. Streptococcus pyogenes strains M1 and M57 express streptococcal inhibitor of 
complement (SIC) which inhibits TCC formation by preventing the uptake of the C5b-C7 onto 
the cell membranes 92. In addition, herpes simplex virus type 1 and 2 use the transmembrane 
protein gC1 and gC2 to bind C3b, thus accelerating the decay of the alternative pathway C3 
convertase 93. gC1 also inhibits the interaction of C3b with C5 and Factor P 94. Schistosoma 
and Trypanosoma parasites express complement C2 receptor trispanning protein, which 
disrupts the interaction between C2 and C4, thus interfering with the classical pathway C3 









Expression of proteases to allow proteolytic degradation is an additional strategy utilized 
by microbial pathogens to inactive host complement attack. For example, the streptococcal 
C5a peptidase (ScpB) expressed by Group B streptococci cleaves and inactivates chemokine 
C5a, thereby providing a significant advantage for mucosal colonization. C. albicans produces 
secreted aspartic proteinases (Saps), like Saps 1, 2 and 3 which degrade C3b, C4b and C5, 
thereby blocking complement activation and effector function, such as C3b and C4b surface 
depositions 96. In addition, Pseudomonas spp. proteases (PaE and PaAP) 97 and 
Porphyromonas spp. proteases (PrtH) 98 cleave C3 into non-functional fragments, thus 
inhibiting C3b deposition and complement activation at the bacterial surface.  
 
2.5.1.2 Evasion from cellular immune responses 
In addition to complement attack, infectious microbes encounter cellular immune responses 
mediated by different cell types. Therefore, microbial pathogens have evovled strategies to 
escape from these immune surveillances for an infection. According to mechanisms, evasion 
from the cellular immune responses can be further classified into four sub-types, (i) escaping 
from phagocyte responses; (ii) interfering with the cytokine release and blocking the cytokine-
receptor interaction; (iii) interfering with the antigen presentation; and (iv) interfering with 
effector function of B and T cells. Examples and the exact mechanism for each type of the 
cellular immune evasion are listed below (Table 3).  
 
2.5.2 Tissue invasion 
In order to spread and cause invasive disease microbial pathogens aslo found ways to 
overcome tissue barriers including extra-cellular matrix, nonphagocytic host cells, like 

















            Table 2 Human complement regulators bound by pathogens for complement evasion 
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Candida albicans                 
Aspergillus spp.                        
Gpm1    
?   
Factor H,  FHL-1                 
C4BP    Factor H,  FHL-1                   CFHR1                   
? C4BP    
αvβ3 integrin-
like protein vitronectin     
Bacteria 
Actinobacillus 
actinomycetemcomitans   
Omp 100                               Factor H 
Borrelial afzelii                    BaCRSAP-1,2,3                    Factor H,  FHL-1                 
 
BaCRASP-4,5                       Factor H 
Borrelia burgdorferi                                                                BbCRSAP-1,2                       Factor H,  FHL-1                 
BbCRSAP-3,4,5, HcpA        Factor H CFHR1 
Factor H,  FHL-1                 Borrelial  Hermsii               FhbA 
BhCRASP-1                         Factor H    CFHR1                                                                                                                        
Escherichia coli                     Stx2     Factor H 
? Factor H 
OmpA   
Escherichia coli K1                                                                                                                            
C4BP                 
CD59   ? 
Haemophilus influenzae            ? Factor H,  FHL-1                 
? C4BP 
Hsf vitronectin 
Leptospira interogans           LenA (LfhA)                        Factor H CFHR1        
LenB Factor H 
 
UspA1,2 C4BP  
UspA2                                                                  
Moraxella catarrhalis           
vitronectin   
Neisseria gonorrhoeae          Por1A   Factor H 
Por1A, Por1B                                                           C4BP 
Neisseria meningitidis           fHbp (GNA 1870) Factor H 
Por A                                                                         C4BP   
Pseudomonas aeruginosa     Tuf Factor H CFHR1      
      
Staphylococcus aureaus        Factor H CFHR1 
?    
Sbi     
vitronectin 
?    clusterin 
Streptococcus  pyogenes        
Fba 
M protein                                Factor H,  FHL-1                 C4BP   
Factor H,  FHL-1        
Scl1.6                                         Factor H CFHR1   
SIC clusterin    
Streptococcus pneumoniae Bac, Hic, PspC                          Factor H 
PspC 4.4 C4BP 
? vitronectin 
Parasites 
Onchocerca volvulus                 microfilari
ae         
Factor H 
Echinococcus granulosus         Factor H ?        
HIV     gp41, gp120                                 Factor H 
Westnilvirus    NS1   Factor H 
Virus 







Table 3 Immune evasion and tissue invasion of microbial pathogens 
Types                                          Mechanisms                             Examples                            References 
Evasion of cellular immune responses                 
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Modulation of the 
cytokine release 
1. Induction of anti-inflammatory 
cytokine release by favoring TLR2 
activation, instead of TLR4 




Bordetella pertussis (FHA) 
Yersinia enterocolitical (LcrV) 
2. Inducing anti-inflammatory 
cytokine IL-10 release, thus 
suppressing ΙΝF- γ production by 
antigen specific T cells and down-
regulating host immune responses 
1. Inhibition on C3d and CR2 
interaction, thus preventing 
CR2-mediated B cell 
activation and maturation 
Interfering with the 
antigen presentation 
S. aureus (Efb and Ehp) 
2. Diminishing the ability of 
antigen processing cells to 
degrade internalized antigens 
Helicobacter pylori (VacA) 
3. Inhibition on the MHC 
molecule surface expression on 
infected host cells 
Chlamydia trachomatis 
Interfering with effector 
function of T and B cells 
1. Inhibiting tyrosine phosphorylation 
of T and B cell receptors, thereby 
suppressing antigen-specific T cell 
activation and IL-2 release, and up-
regulating of the costimulatory 
molecule CD86 after B cell receptor 
engagement with antigens 
Yersinia  pseudotuberculosis  
(YopH),  
2. Shedding proteins to block 
CEACAM1 on T cell surfaces, 
thereby inhibiting the activation 






epithelial and endothelial 
cell barriers 
1. Secretion or expression of lytic 
enzymes 
2. Recruitment of host 
plasminogen onto pathogen 
cell surfaces 
C. albicans, 
Pseudallescheria boydii  
C. albicans, Pseudomonas 
aeruginosa, Cr. neoformans, 
Borrelia spielmanii, group A 
streptococci 
1. Induction of passive uptake 
by host cells 
C. albicans 
A. fumigatus 
2. Active penetration mediated by 
production of lytic enzymes C. albicans 
3. Induction of membrane ruffling 
and projection of microvilli that 
surround the organisms and pull 
them into the cell
Cr. neoformans 
2. Induction of programmed host 
cell death 
 
3. Persistent in the intracellular 
host phagocytes 
1.Escaping PRRs recognition of 
phagocytes by shielding PAMPs  
4. Shedding a decoy in a 
surrounding of pathogens 
Escape from                        
phagocytes response 
response 
C. albicans  (β-glucan) 













2.6 Candida albicans 
 
2.6.1 General properties  
Candida albicans is one of the most important members of the yeast genus and is a causal 
agent of opportunistic superficial and systemic infections in humans. C. albicans has two 
different forms, yeast and hyphal forms. C. albicans has a thick cell wall, an outer structure 
which protects the fungus from environmental stress like osmotic pressure and defines the 
shape and physical strength of the fungal cell. The cell wall of C. albicans is a highly complex 
structure composed of glucans (β-1,3 and β-1,6 glucans), chitin, GPI-anchored protein and 
mannoproteins inserted in a network of polysaccharides (Figure 8). This fungal cell wall plays 
several important roles for C. albicans survival and initiating an infection: (i) first coming into 
contact with host cells; (ii) carrying important antigenic determinants; (iii) being responsible 




                                                    Figure 8. The cell wall of C. albicans 
 
Under normal circumstances, C. albicans is a commensal fungus which usually resides as part 
of mucosal microflora (oral cavity, gastrointestinal tract or the vagina) 188. About 80% of the 
human population carries C. albicans with no harmful effects. However, C. albicans can turn 
from a commensal yeast into an infectious pathogen especially in patients with some 
predispositions. These predispositions include: (i) the disrupted balance of the normal flora; (ii) 
impaired barriers; and (iii) immunosuppression which is due to cancer treatments, 
immunosuppressive therapy, long-term catheterization, use of broad spectrum antibiotics, 
steroids, or diseases such as AIDS. C. albicans infection ranges from superficial to systemic 
infection. Despite currently applied anti-fungal therapies, both mortality and morbidity 
mediated by infection are still unacceptably high 189-191. More than 75% of people with 
systemic candidal infection die. Moreover, resistant C. albicans strains are continuously 
increasing in recent years. C. albicans is the most frequently isolated fungal pathogen from 















frequently affected. In addition, lung, liver, and spleen can also be infected by C. albicans. 
Signs and symptoms of a candidal infection in patients vary depending on the location of the 
infection. Oral candidiasis, called thrush, is characteristic of thick, white lacy patches on top of 
a red base. Oral candidiasis may also make the tongue look red without the white coating. 
Vaginal yeast infection is a white cheesy discharge that typically itches and irritates the vagina 
and the surrounding outer tissues.   
 
2.6.2 Virulence factors and evasion strategies of C. albicans 
Upon the course of infection, C. albicans encounters host surfaces, the outer layer of the skin, 
tissue barriers as well as humoral and cellular immune responses. Therefore, virulence factors 
and evasion strategies utilized by C. albicans to initiate an infection consist of: (i) the ability to 
adhere and colonize onto host epithelial surfaces; (ii) tissue invasion by production or 
acquisition of tissue damaging enzymes, as well as morphogenesis or expression of surface 
invasion;  and (iii) evasion of various immune surveillances, such as complement evasion and 
evasion of cellular response of the innate immunity.  
 
2.6.2.1 Adhesion and invasion of the epithelium by C. albicans 
Adhesion and colonization of C. albicans onto host epithelial cell is the first step for invasion 
and crossing the epithelium. This step is mediated by surface expressed adhesins. The adhesins 
are mostly mannoproteins. Both the protein and carbohydrate portions are involved in the 
adherence. For example, Agglutinin-like sequence (Als) family, hyphal cell wall protein 1 
(Hwp1) and integrin-like protein 1 (Int1) mediate C. albicans in adhesion and colonization 192-
194
. Hwp1, a developmentally regulated adhesin of germ tubes and hyphae, attaches to buccal 
epithelial cells by an unconventional, transglutaminase-mediated mechanism of 
adhesion 195,196. In addition, transcription of several genes, such as PHR1, PRA1, FKH1, TEF1 
HYR1 and EED1 is up-regulated during the oral infection 197,198. During adhesion onto the host 
epithelial cell surfaces, C. albicans secretes proteases like Saps 9 that degrades and deactivates 
host anti-microbial peptide secreted by epithelial cells, thereby allowing C. albicans to avoid 
the anti-microbial attack on the epithelial cell surfaces 199. Following adhesion, C. albicans 
induces the hyphal production and secretes multiple extra-cellular hydrolytic enzymes (e.g., 
Saps, Plb, and Lip families) that digest or destroy cell membranes, and degrade host surface 
molecules to further break down and enter host epithelial cell barriers 200. In addition, 
C. albicans induces host epithelial cells to produce pseudopods that mediate the accumulation 







C. albicans can invade epithelial cells by both passive uptake and active penetration. However, 
these two routes are exploited to a different extent which depends on the types of host cells 
faced by the fungus 201. During superficial infection, C. albicans is often hidden within host 
epithelial cells, which is suggested that the intracellular location protects C. albicans from the 
host immune attack, such as complement attack and phagocytosis 156. 
 
2.6.2.2 Complement evasion of C. albicans 
Following invading epithelial barriers, C. albicans gains access to the blood stream. However, 
C. albicans immediately encounters the complement response. To combat the complement 
attack, C. albicans captures host complement regulators Factor H, FHL-1 and C4BP from 
human plasma to its surface 79,99,100,103. Attached to the surface, all these complement 
regulators retain complement regulatory functions, which allows C. albicans to evade immune 
and complement attack. The phosphoglycerate mutase (Gpm1p) is the first Factor H binding 
protein identified from C. albicans yeast cells. Gpm1p, also termed complement regulator 
acquiring surface protein 1 (CRASP1) 101 mediates C. albicans acquiring Factor H and FHL-1 
from NHS for immune and complement evasion. Gpm1p binds Factor H via two contact sites, 
SCRs6-7 and SCRs19-20, and binds FHL-1 via SCRs6-7. A Gpm1p deficient yeast mutant 
shows reduced Factor H binding, but not completely, which indicates that an additional Factor 
H binding protein exists at C. albicans surface. In addition, C. albicans binds C4BP, a 
classical pathway complement regulator. Binding domains within C4BP for C. albicans were 
mainly localized in SCR1 and SCR2 of the α-chain of C4BP 100. However, which protein from 
C. albicans that binds C4BP still remains unknown.  
 
Vitronectin is a terminal complement pathway inhibitor. The yeast form of C. albicans 
expresses a receptor, which is antigenically related to the host vertebrate αvβ3 integrin 
receptor, so called αvβ3 integrin-like protein. This integrin-like receptor acquires vitronectin 
to yeast cell surface to inhibit TCC formaion, thereby controlling the terminal complement 
pathway attack 202. Some clinical isolates of C. albicans bind vitronectin 203, which shows an 
example that recruitment of vitronectin plays a role for C. albicans infection in an in-vivo 
situation. This binding is strongly inhibited by heparin, which indicates the involvement of the 
glycosaminoglycan-binding region of vitronectin in Candida-vitronectin interaction 204.  
 
In addition to the immediate acquisition of host complement regulators for complement 







human complement components C3b, C4b and C5, thereby interfering with the complement 
activation cascade and the effector functions 96. 
 
2.6.2.3 Evasion of host cellular immune responses by C. albicans  
In addition to complement attack, locally resident and newly attracted phagocytes are the next 
“enemy” for C. albicans. One strategy used by C. albicans is to shield the surface PAMPs to 
escape PRR recognition of the phagocytes. On C. albicans cell wall, β-glucan is a common 
conserved component which binds dectin-1 and favors recognition of C. albicans by human 
phagocytes. However, during the hyphal growth, C. albicans surface mannans shield β-glucan 
from recognition by dectin-1, thereby avoiding the phagocytosis by phagocytes 151,152. 
  
In addition, cytokines are a group of immune effector molecules that are used for cellular 
communication in both the innate and the adaptive immunity. C. albicans uses multiple 
mechanisms to interfere with or modulate the cytokine release and cytokine-receptor 
interaction, thereby modulating cytokine-mediated host immune responses. For example, C. 
albicans hyphae is able to evade TLR4, but favor TLR2 activation. By avoiding TLR4 
recognition, C. albicans inhibits Th1-response mediated pro-inflammatory cytokine release 
(like IFN-γ), thereby down-regulating the further host immune response mediated by pro-
inflammatory cytokines. In parallel, C. albicans, by favoring TLR2 activation, initiates the 
TLR2 mediated Th2 response that induces an anti-inflammatory cytokine response, like IL-10, 
thereby inhibiting macrophage activation and oxidative burst 160,205,206. 
 
If evasion from the recognition by host phagocytes fails, C. albicans inside phagocytes 
initiates NO-scavenging flavohemoglobin gene expression, induces an anti-NO defense 
mechanism, therefore converting NO to less toxic molecules 207. Furthermore, C. albicans also 
actively suppresses the production and release of reactive oxygen species (ROS), thereby 
inhibiting killing or destruction of fungus by phagocytes 208. In addition, C. albicans resists the 
intracellular killing and escapes from the phagocytes by slow growth, development of hyphal 
growth and alternative carbon utilization 209.  
 
2.6.2.4 Adhesion and invasion to the endothelium by C. albicans   
For a systemic and disseminated infection, C. albicans has to enter into the blood stream, 
spread through out the body, overcome the blood vascular endothelial cell and invade target 







barriers: (i) phagocytosis of C. albicans by host leukocytes, which then dispense across the 
endothelial cell lining of blood vessels; (ii) the passage of C. albicans between the endothelial 
cells, which likely happens in vascular beds of organs like kidney; and (iii) the endocytosis of 
C. albicans by the endothelial cells via ligand-receptor interaction 210. Agglutinin-like 
sequence 3 (Als3) is an invasin expressed by C. albicans which mediates the endocytosis of 
the fungus into endothelial cells. Als3 binds to the N-cadherin expressed on endothelial cell 
surfaces. This interaction induces the phosphorylation of the endothelial surface proteins, thus 
causing the rearrangement of the endothelial cell microfilaments to produce pseudupods and 
initiate the edocytosis 182. In addition, Hgc1 is a newly discovered C. albicans protein which 
mediates dynamic C. albicans-endothelium adhesion during circulation 211. It also suggests 
that C. albicans by internalization into the endothelial cell hides from the detection by 
professional phagocytes 156. 
 
2.6.2.5 Adhesion and invasion of extra-cellular matrix by C. albicans 
Upon an infection, C. albicans also encounters extra-cellular matrices which mediate the cell 
assembled and bound together in tissues. In order to cross these impact barriers, C. albicans 
either secretes lytic enzymes (like Saps or lipases) 200, or acquires human plasminogen onto 
surface. Surface attached plasminogen is activated into plasmin by activators (uPA or tPA) 
and degrade extra-cellular matrices, thereby mediating C. albicans tissue invasion. Eight 
plasminogen binding proteins are expressed on C. albicans surface, such as alcohol 
dehydrogenase, thioredoxin peroxidase, catalase, transcription elongation factor, 
glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerate 
mutase (Gpm1p) and fructose bisphosphate aldolase101,212.   
 
Besides these efficient evasion mechanisms, the biofilm formation is another virulence factor, 
which induces C. albicans resistant to a range of anti-fungal agents in current clinical use, 
including amphotericin B and fluconazole. Therefore, biofilm formation appears to be one of 













2.7 Aspergillus fumigatus 
 
2.7.1 General properties  
Aspergillus fumigatus is a fungus which belongs to the Aspergillus genus and is one of the 
most common Aspergillus species that cause diseases in immuno-compromised individuals. 
A. fumigatus is widespread in nature, typically found in soil and decaying organic matter, such 
as compost heaps. In nature, A. fumigatus plays an essential role in carbon and nitrogen 
recycling. Colonies of the fungus produce thousands of minute gray-green conidia that readily 
become airborne. Everybody inhales hundred of spores per day. These spores are quickly 
eliminated by host immune system in healthy individuals. However, in immuno-compromised 
individuals, such as organ transplant recipients and people with AIDS or leukaemia, the 
fungus becomes pathogenic, evade the host weakened defenses and cause a range of diseases, 
generally termed aspergillosis. 
 
2.7.2 Virulence factors and evasion strategies of A. fumigatus 
Similar to C. albicans, virulence factors and evasion strategies utilized by A. fumigatus to 
initiate an infection include: (i) the ability to adhere and colonize onto host epithelial surfaces; 
(ii) tissue invasion by production and acquisition of tissue damaging enzymes, as well as 
expression of surface invasion; and (iii) evasion of various immune surveillances, such as 
complement evasion and evasion of cellular response of the innate immunity.  
 
2.7.2.1 Adhesion and invasion of the epithelium by A. fumigatus 
Invasive aspergillosis is initiated by inhalation of conidia. These conidia are then deposited in 
the alveoli. Subsequently, the conidia adhere and invade the epithelial cell lining of the alveoli, 
which is a crucial step for establishment of aspergillosis. In this process, A. fumigatus induces 
its own endocytosis mainly by type II pseumocytes (great alveolar cells). Type II pseumocytes 
contact with A. fumigatus and produce pseudopods that engulf the fungus 180. Once 
internalized by type II pseumocytes, the conidia translocate to the late endosome/lysosome. 
The internalized conidia remain viable for rather long periods compared to conidia within 
macrophages, and also limit the release of pro-inflammatory cytokines IL-6 and IL-8 156,181. 
Eventually conidia germinate and escape from the endosome, penetrate the plasma membrane 










2.7.2.2 Complement evasion of A. fumigatus 
After overcoming the epithelial cell barrier, A. fumigatus encounters the complement attack. A. 
funigatus conidia acquire human complement regulators like Factor H, FHL-1 and CFHR1 for 
complement evasion. Conidia bind Factor H via N-terminal SCRs1-7 and SCR20, and bind 
FHL-1 via SCRs1-7. Surface bound Factor H maintains regulatory activity and assists Factor I 
to cleave C3b or dissociates the C3 convertase. This inhibitory effect therefore inhibits the 
complement activation and the immune effector function, like inflammation and phagocytosis. 
In addition, A. fumigatus hyphae produce a water-soluble factor that decreases C3b deposition 
on the fungal surface and interferes with the C3b mediated phagocytosis and killing of the 
fungus by human phagocytes 214. Furthermore, A. fumigatus secrets proteolytic enzymes that 
degrade the central component C3, thereby blocking the complement attack 215.  
 
2.7.2.3 Evasion of host cellular immune responses by A. fumigatus 
Facing the cellular response, A. fumigatus induces hyphae formation to evade the TLR4 
recognition, thereby inhibiting TLR4 mediated pro-inflammatory cytokine release, like IFN-γ 
and subsequent host immune response 216. Similar to C. albicans, hiding inside the non-
phagocytic cells is another strategy to escape from the phagocytic recognition. In addition, 
several fungal metabolites interfere with the phagocytosis. For example, aflatoxins depress 
phagocytosis, intracellular killing and spontaneous superoxide production by macrophages 217. 
Gliotoxin inhibits macrophage adhesion and phagocytosis of the fungus in vitro without 
leading to cell death and prevents spleen cells from inducing alloreactive cytotoxic T cells 218. 
In addition, A. fumigatus conidia release a “conidia inhibitory factor”, which binds the 
contractile elements of the cell cytoplasma, thereby blocking chemoattractant-induced PMNs 
migration 219-221. A. fumigatus conidia also release A. fumigatus diffusible product (AfD), 
which inhibits the production of the pro-inflammatory cytokine transcription in rat alveolar 
marophages 222. When phagocytosed by professional phagocytes, A. fumigatus is still able to 
resist the oxidants, or fails to stimulate the respiratory burst in macrophages 223,224.  
 
2.7.2.4 Adhesion and invasion of the endothelium by A. fumigatus 
Invasion of the blood vessels is a key feature of invasive aspergillosis 225,226. A. fumigatus 
invade the vasculature and enter into the blood stream by passing from the abluminal to the 
luminal surface of the pulmonary endothelial cells, which leads to the disruption of the 







disseminates throughout the body. Finally, the hyphae penetrate the luminal surface of 
vascular endothelial cells via induction of its own endocytosis to invade host organs 180,227,228.  
 
2.7.2.5 Adhesion and invasion of extra-cellular matrix 
Intact A. fumigatus conidia adhere to extra-cellular matrix compounds like laminin, fibronectin, 
collagen type 1 and 4 and also to fibrinogen via surface expressed adhesin. The laminin 
binding protein of the fungus is found as a 72 kDa cell wall glycoprotein, called extra-cellular 
thaumatin domain potein (AfCalAp). Following adhesion, A. fumigatus produce lytic enzymes 
to degrade the extra-cellular matrices for tissue invasion. For example, an extra-cellular 
elastinolytic alkaline proteinase (AFAlp) is able to degrade collagen, fibrin, fibrinogen and 
elastin 229. In addition, A. fumigatus also binds plasminogen and utilizes it to degrade the 
extra-cellular matrix 103 . 
 
2.8 Streptococcus pneumoniae 
 
Streptococcus pneumoniae is Gram-positive and belongs to the Streptococcus genus. As a 
significant human pathogenic bacterium, S. pneumoniae was recognized as a major cause of 
pneumonia in the late 19th century. Furthermore, this bacterial pathogen cause many other 
types of pneumococcal infection, including acute sinusitis, otitis media, meningitis, bacteremia, 
sepsis, osteomyelitis, septic arthritis, endocarditis, peritonitis, pericarditis, cellulitis, and brain 
abscess. S. pneumoniae is the most common cause of bacterial meningitis in adults and 
children, and is one of the top two isolates found in the ear infection, called otitis media. 
S. pneumoniae is part of the normal upper respiratory tract flora. However, S. pneumoniae is 
also opportunistic and can become pathogenic under the suppressed immune system. 
Pneumolysin (an anti-phagocytic capsule), various adhesins and immunogenic cell wall 
components are major virulence factors. 
S. pneumoniae evolved many different evasion strategies for establishing an infection. For 
example, S. pneumoniae utilizes Pneumococcal surface protein C (PspC) to acquire Factor H 
onto the bacterial surface, which mediates complement evasion 230. However, the effect of 
PspC on complement attack varies from the strain background and capsular serotype 231. In 









2.9 Aim of the project 
 
C. albicans is the most frequently isolated fungal pathogen from infected individuals. 
Infections with C. albicans range from superficial to systemic disorders 233. Despite currently 
applied anti-fungal therapies, both mortality and morbidity mediated by C. albicans are still 
unacceptably high 189-191. The aim of my PhD work was to identify and characterize central 
immune evasion proteins of this human pathogenic yeast C. albicans.  
 
C. albicans utilize human complement regulators, Factor H, FHL-1 and C4BP for complement 
evasion. In order to identify and characterize C. albicans encoded proteins that bind human 
complement regulators, via screening an expression cDNA library, I identified the pH-
regulated antigen 1 (Pra1) as a fungal surface protein that binds Factor H and FHL-1. Pra1 
which was originally identified as a fibrinogen binding protein, is a yeast surface protein and 
is also released 234,235. The released Pra1 protein binds to the integrin receptor CR3 
(CD11b/CD18; αMβ2) expressed on the surface of human leukocytes 235. The transcription of 
PRA1 gene is up-regulated upon co-culture of C. albicans with human epithelial and 
endothelial cells 236. However, how Pra1 mediates C. albicans complement evasion; whether 
and how Pra1 mediates C. albicans contact with human cells; and whether and how Pra1 
functions differently at different sites are still unknown. Therefore, the goals of this project 
was to define the different functions of Pra1 at the different locations, i.e. (i)  at the yeast 












3. Overview of the inserted manuscripts  
1. Immune evasion of the human pathogenic yeast Candida albicans: Pra1 is a Factor H, 
FHL-1 and plasminogen binding surface protein. 
           Shanshan Luo, Sophia Poltermann, Anja Kunert, Steffen Rupp, Peter F. Zipfel 
           Mol Immunol. 2009 Dec; 47(2-3):541-50.  
            Major aspects of the manuscript 
In this manuscript, the pH-regulated antigen 1 (Pra1) is identified as a novel Factor H 
binding protein by screening a C. albicans cDNA expression library. Pra1 was 
recombinantly expressed and purified in Pichia pastoris system. Candida Pra1 is 
expressed on the surface and also released to culture supernatant. As a surface protein, 
Pra1 acquires two human complement regulators Factor H, FHL-1 as well as 
plasminogen, mediates complement evasion, and degradation of extra-cellular matrices. 
A Pra1 overexpressing strain with about twofold Pra1 level on the surface binds more 
Factor H and plasminogen. As a released protein, Pra1 enhances complement control 
of Factor H in direct vicinity of the yeast. 
 
Own contribution and contribution of the coauthors to the manuscript 
- Shanshan Luo has planed, performed, and interpreted the following experiments: 
expression and purification of Pra1 by FPLC, characterization of Pra1 anti-serum; 
ELISA and ligand affinity blotting analysis of Pra1 binding to Factor H, FHL-1 and 
plasminogen; localization of Pra1 binding domains within Factor H and FHL-1; 
functional assay of bound Factor H, FHL-1 and plasminogen; flow cytometry, confocal 
microscopy, Western blotting and Candida ELISA for analyzing Pra1 location; 
comparison of Factor H and plasminogen binding to a Pra1 overexpressing strain with 
wild type strain; Shanshan Luo also wrote the manuscript. 
- Sophia Poltermann assisted in Candida ELISA and confocal microscopy assay. 
- Sophia Poltermann and Anja Kunert screened the cDNA library and identified Pra1 as 
a Factor H binding protein. 
- Steffen Rupp provided a Pra1 overexpressing strain.  
- Peter F. Zipfel designed the study, interpreted the results and wrote the manuscript. 
 
            
 






2. Secreted pH-regulated antigen 1 of Candida albicans blocks activation and conversion 
of complement C3    
          Shanshan Luo, Andrea Hartmann, Hans-Martin Dahse, Christine Skerka, and 
          Peter F. Zipfel. J Immunol. Jul 19, 2010 (in press). 
            Major aspects of the manuscript 
In this manuscript, Pra1, which is secreted by human pathogenic yeast C. albicans, was 
identified as the first fungal complement inhibitor. Pra1 by complexing C3 in solution 
blocks the conversion of this central complement component by C3 convertases. 
Thereby, Pra1 inhibits further complement activation, amplification and progression, 
and down-stream complement effector functions, such as C3a and C5a mediated 
inflammatory t and C3b/iC3b mediated phagocytosis.  
 
Own contribution and contribution of the coauthors to the manuscript 
Shanshan Luo has planed, performed, and interpreted the following experiments: 
ELISA analysis of Candida Pra1 and S. aureus Efb binding to C3 and C3b; preparation 
of Factor H depleted human serum; hemolytic assay, Western blotting and C5a ELISA 
analysis of Pra1 inhibiting on complement activation both in NHS and in Factor H 
depleted human serum; the mechanism of Pra1 mediated inhibition on complement 
activation; effect of Pra1 on C3a generation, flow cytometry analysis of C3b/iC3b 
surface deposition and phagocytosis assay; evaluation of native Pra1 concentration in 
the culture supernatant of C. albicans. Shanshan Luo also wrote the manuscript. 
- Andrea Hartmann has performed the differentiation of the extra- and intra- cellular 
yeast cells which interact with human macrophages by confocal microscopy. 
- Hans-Martin Dahse assisted in the cell culture and phagocytosis assay by flow 
cytometry. 
- Christine Skerka discussed the results and wrote the manuscript. 
- Peter F. Zipfel designed the study, interpreted the results and wrote the manuscript.  
          










3. The pH-regulated antigen 1 of Candida albicans interacts with C4b-binding protein 
(C4BP) and mediates fungal contact with human endothelial cells 
      Shanshan Luo, Anna M. Blom, Steffen Rupp, Bernhard Hube, Uta-Christina Hipler, 
          Christine Skerka, Peter F. Zipfel.   
          Manuscript in revision at the Journal of Biological Chemistry, 2010  
           Major aspects of the manuscript 
 
In this manuscript, I identified Pra1 as the first fungal C4BP binding protein from 
C. albicans. C4BP bound to Pra1 via SCR4, SCR7 and SCR8 maintains cofactor 
activity. A Pra1 overexpressing strain binds twice C4BP, and Pra1 knock out mutant 
showes reduced C4BP binding, compared to the wild type strain. Upon co-cultivation 
of C. albicans with human cells, Pra1 surface expression level is up-regulated. By 
binding to HUVEC cells, surface Pra1 mediates C. albicans infection to human 
endothelial cells. A homozygous nucleotide exchange (A73G) in PRA1 gene that 
causes an Asn25Asp exchange on the protein level was identified in all tested strains. 
 
Own contribution and contribution of the coauthors to the manuscript 
- Shanshan Luo has planed, performed and interpreted the following experiments: 
ELISA analysis of Pra1binding to C4BP, competition of Factor H and C4BP binding to 
Pra1, and effect of NaCl on Pra1-C4BP interaction; localization of Pra1 binding 
domains within C4BP; cofactor assay; flow cytometry and confocal microscopy 
analysis of binding of C4BP to a Pra1 overexpressing , a Pra1 knock out and a wild 
type C. albicans strains, and binding of Pra1 to human cells; flow cytometry analysis 
of Pra1 expression level at stimulated C. albicans surface; adhesion and invasion assay; 
analysis of Pra1 surface expression and sequence variation in different clinical isolates; 
Shanshan Luo also wrote the manuscript. 
- Anna M. Blom provided the recombinant C4BP, the C4BP deletion mutants, the 
monoclonal antibody (MAb) 67, MAb 104 and polyclonal rabbit C4BP anti-serum, 
discussed the results and wrote the manuscript. 
- Steffen Rupp had provided a Pra1 overexpressing C. albicans strain. 
- Bernhard Hube provided a GFP labeled C. albicans strain and a Pra1 knock out 
C. albicans strain. 
- Uta-Christina Hipler provided clinical C. albicans isolates. 






- Christine Skerka discussed the results and wrote the manuscript.   






































4. Complement regulator Factor H mediates a two-step uptake of Streptococcus 
pneumoniae by human cells. 
           Vaibhav Agarwal, Tauseef M. Asmat, Shanshan Luo, Inga Jensch, Peter F. Zipfel, and 
           Sven Hammerschmidt 
           J Biol Chem. 2010 Jul 23; 285(30):23486-95. 
Main points of the manuscript 
 
In this study, the way how bacterial-bound Factor H promotes pneumococcal uptake 
and phagocytosis by human cells was identified. Anti-CD11b and anti-CD18 reduce 
Factor H-promoted uptake by CR3 expressing epithelial cells and PMNs. As a CR3 
binding protein, Candida Pra1 blocks Factor H-promoted pneumococcal uptake by 
lung epithelial cells as well as phagocytosis by PMNs, but does not affect adherence. 
Invasion of pneumococci via Factor H requires the dynamics of host-cell actin 
microfilaments. Pneumococcal uptake depends on protein tyrosine kinases and 
phosphatidylinositol-kinase (PI3K).  
 
Own contribution and contribution of the coauthors to the manuscript 
- Shanshan Luo has planed, performed and interpreted recombinant Pra1 expression and 
purification by FPLC and characterization of polyclonal Pra1 anti-serum.     
- Vaibhav Agarwal has planed, performed and interpreted the following experiments: 
Pneumococcal host cell adherence and invasion assay; Flow cytometric analysis of 
Factor H binding to pneumococci; fluorescence microscopy assay for Pneumococci 
attached to host epithelial cells. Vaibhav Agarwal also contributed to the writing of the 
manuscript. 
- Peter F Zipfel provided monoclonal antibody against SCRs19-20, discussed the results 
and wrote the manuscript. 
- Sven Hammerschmidt designed the study and wrote the manuscript. 












4.1  Immune evasion of the human pathogenic yeast Candida albicans: Pra1 is a 
Factor H, FHL-1 and plasminogen binding surface protein. 
            Shanshan Luo, Sophia Poltermann, Anja Kunert, Steffen Rupp, Peter F. Zipfel 























































































































































































































































































































































































































































































































































4.2 Secreted pH-regulated antigen 1 of Candida albicans blocks activation and 
conversion of complement C3. 
            Shanshan Luo, Andrea Hartmann, Hans-Martin Dahse, Christine Skerka,  



































































































































































































































































































































































































4.3 The pH-regulated antigen 1 of Candida albicans interacts with C4b-binding 
protein (C4BP) and mediates fungal contact with human endothelial cells. 
       Shanshan Luo, Anna M. Blom, Steffen Rupp, Bernhard Hube, Uta-Christina Hipler, 
           Christine Skerka, and Peter F. Zipfel  
           Manuscript in revision at the Journal of Biological Chemistry, 2010  







































































































































































































































































































































































































































































































































































































































































































































4.4 Complement regulator Factor H mediates a two-step uptake of Streptococcus 
pneumoniae by human cells. 
           Vaibhav Agarwal, Tauseef M. Asmat, Shanshan Luo, Inga Jensch, Peter F. Zipfel, and 
















































































































































































































































































































































































































































































































































































Function of Pra1 as a surface protein of C. albicans 
 
Surface Pra1 binds the human complement regulators Factor H, FHL-1, C4BP as well as 
plasminogen 
Acquisition of human complement regulators is a general immune evasion strategy used by 
C. albicans, as well as many other pathogens, such as A. fumingutas and 
S. pneumoniae 99,100,103,230. C. albicans acquires human complement regulators Factor H, FHL-
1, and C4BP to the fungal surface and utilizes these regulators for complement evasion 99,100. 
Through screening a cDNA library, Pra1 was identified as a Factor H binding protein. Pra1 is 
a strain-specific glycosylated protein composed of 299 amino acids 193,234,237,238, which has 
several consensus sites for N-linked as well as O-linked glycosylation. Based on the 
glycosylation, treatment of the native Pra1 protein with endoglycosidase H reduced the 
molecular mass by ca. 25% 237. Using the specific anti-serum, I localized Pra1 at the surface of 
both the yeast and hyphal forms of C. albicans and showed that Pra1 is also released into the 
culture supernatant which is consistent with the previous study 234,235,237. As a surface protein, 
Pra1 is primarily localized at the tip of C. albicans hyphae, suggesting an important role of 
Pra1 upon contact with host tissues and surfaces during infection (manuscript 1). 
 
Pra1, also termed Candida CRASP2 (complement regulator acquiring surface protein 2), is a 
novel Factor H and FHL-1 binding fungal surface protein identified from human pathogenic 
yeast C. albicans. Pra1 binds the human complement regulator Factor H, via N-terminal 
SCRs5-7 and also C-terminal SCRs16-20, and binds FHL-1 via SCRs5-7. This binding 
property is similar, but not identical to Candida moonlighting protein phosphoglycerate 
mutase 1 (Gpm1p), also termed Candida CRASP1. Gpm1p binds Factor H via SCRs6-7 and 
SCRs19-20, and binds FHL-1 via SCRs6-7 101. The interaction between Pra1 and Factor H is 
affected by NaCl, which implies that this binding is mostly based on ionic interaction between 
amino acids (manuscript 1). 
 
A Pra1 specific anti-serum inhibits binding of Factor H and FHL-1 to C. albicans by ca. 17% 
and 40%, respectively (manuscript 1), which indicates that native Pra1 at the surface of the 
yeast binds Factor H and FHL-1. The relative low level of reduction is explained by the 
existence of additional Factor H and FHL-1 binding proteins expressed by C. albicans. For 







In this work, Pra1 was also identified as the first fungal C4BP binding protein from 
C. albicans. Candida Pra1 binds both serum derived and recombinant C4BP. The Pra1-C4BP 
interaction is of ionic interaction and is affected by NaCl. This type of interaction is similar to 
the Pra1-Factor H interaction, but is different from that of the streptococcal M proteins-C4BP 
interaction, which is of hydrophobic nature 137. Candida Pra1 binds C4BP via domains SCR4, 
SCR7 and SCR8, which is different from the complement inhibitory activity sites, SCRs1-3 
56,239
. Thereby, binding of Pra1 to C4BP via C-terminal domains SCR4, 7 and 8 orientates 
C4BP in such a way that the protein better exposes the functional regions to the outside. 
Rather similar attachment of other microbial proteins to C4BP has been defined for ubiquitous 
surface protein A 1 (UspA 1) and UspA 2 of M. catarrhalis, that bind C4BP via domains 
SCR2 and SCR7 122, outer membrane protein A (OmpA) of Escherichia coli K1 and 
Haemophilus influenzae 118 that bind C4BP via domains SCR3 and SCR8 116. However, 
streptococcal M protein 137 and Neisseria gonorrhoeae porins 240 bind to C4BP via the N-
terminal SCR1. Filamentous hemagglutinin of Bordetella pertussis 241 bind to C4BP via SCR1 
and SCR2. Similarly when analyzing intact C. albicans, the relevant binding domains within 
C4BP were localized to SCR1 and SCR2 for both yeast and hyphal forms 100. This difference 
between C4BP binding to Pra1 and to intact C. albicans cells suggests that the existence of an 
additional C4BP ligand(s) expressed at the surface of C. albicans.  
 
In addition, Pra1 was identified as a new fungal plasminogen binding protein (manuscript 1). 
Pra1-plasminogen interaction is also inhibited by NaCl and is mostly based on ionic 
interaction. However, this effect is not as much pronounced as the Pra1-Factor H interaction. 
In addition, the inhibition of lysine analogue aminocaproic acid on Pra1-plasminogen 
interaction suggests that lysine residues mediate the contact of Pra1 with human plasminogen. 
A Pra1 specific anti-serum inhibits plasminogen binding to C. albicans surface by ca. 12% 
(manuscript 1), which confirms the role of surface Pra1 in mediating Candida-plasminogen 
binding. However, this low level of reduction indicates that additional plasminogen binding 
proteins exist at the C. albicans surface. By a proteomic approach, eight plasminogen binding 
proteins were identified, including alcohol dehydrogenase, thioredoxin peroxidase, catalase, 
transcription elongation factor, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate 
kinase, Gpm1 and fructose bisphosphate aldolase101,212.   
 
A Pra1 overexpressing C. albicans strain, which has about two fold Pra1 levels at C. albicans 







strain (manuscript 1 and 3). However, a Pra1 knock out mutant shows 9%, 22% and 30% 
reduction for Factor H, C4BP and plasminogen binding, respectively, as compared to the wild 
type strain. These binding properties of Pra1 mutants indicate that surface expressed, native 
Pra1 acquires human complement regulators Factor H, C4BP as well as plasminogen from the 
serum to the surface of C. albicans for complement evasion, and that additional Factor H, 
C4BP, as well as plasminogen binding proteins exist at the surface of C. albicans 
(manuscript 3).  
 
C4BP and Factor H binding to Pra1 is not affected by the lysine analogue, while plasminogen 
binding to Pra1 is. This suggests that Factor H and C4BP do not compete with plasminogen 
for Pra1 binding. In addition, C4BP does not compete with Factor H for binding to Pra1 when 
C4BP is less than five times of Factor H amount (manuscript 3), which indicates that Factor 
H and C4BP also bind independently to Pra1 at the physiological mass ratio in human plasma 
(C4BP, ca. 200 µg/ml and Factor H, ca. 500 µg/ml). Thus, human complement regulator 
Factor H, FHL-1, C4BP as well as plasminogen bind to surface Pra1 at non-overlapped 
contact sites. 
 
C. albicans utilizes surface Pra1 for complement evasion and tissue invasion 
C. albicans yeast and hyphae use Pra1 to acquire human complement regulators Factor H, 
FHL-1 and C4BP to the surface. Attached to Pra1, each human regulator is functionally active. 
Factor H, FHL-1 and C4BP bound to Pra1 maintain their cofactor activity and assist Factor I 
to degrade C3b or C4b. Consequently C3b and C4b inactivation will inhibit the formation of 
C3 convertases (C3bBb and C4bC2b) of both the alternative and the classical pathways on the 
fungal surface. This likely prevents further progression of the complement cascade, thereby 
inhibiting down-stream immune effector functions, like phagocytosis, inflammation and lysis 
of microbes. In addition, plasminogen bound to Pra1 is accessible to the activator uPA and is 
converted to the serine protease plasmin. The activated plasmin degrades both the synthetic 
chromogenic substrate S2251 and the native extra-cellular matrix component fibrinogen 
(manuscript 1), thereby aiding C. albicans in tissue invasion. In summary, surface expressed 
Pra1 by binding to human complement inhibitors Factor H, FHL-1 and C4BP, mediates C. 
albicans in complement evasion, and by binding to human plasminogen, mediates the fungal 




















Figure 9. The model of Pra1 mediated complement evasion and tissue invasion of C. albicans. C. albicans 
utilizes surface proteins, like Pra1 and other CRASPs to acquire human complement regulators Factor H, FHL-1 
and C4BP to the surface for immune and complement evasion and binds plasminogen for tissue invasion.  
 
Function of Pra1 as a released protein of C. albicans 
 
Soluble Pra1 is a potent complement inhibitor 
Pra1 is secreted into the culture supernatant by both yeast and hyphal forms of C. albicans. 
Soluble Pra1 is newly discovered as a potent complement inhibitor, which is, -to our 
knowledge-, the first fungal complement inhibitor. Pra1 inhibits C3a generation in a dose 
dependent manner, which indicates that the inhibitory effect of Pra1 on complement activation 
occurs at the level of C3 convertase. Pra1 binds C3 and C3b. However Pra1 does neither 
inhibit C3 convertase formation, nor dissociate a preformed C3 convertase. Further 
characterization indicates that Pra1 displays its complement inhibitory effect in the fluid phase, 
but not on the surface (manuscript 2). Aiming for the inhibitory mechanism, I found that 
secreted Pra1, by complexing C3 in solution inhibits C3 cleavage by C3 convertases, 
consequently blocks complement progression, further formation of the amplification loop and 
the downstream effector functions, such as inflammation and phagocytosis (Figure 10). This 
complement inhibitory mechanism of Pra1 is similar or related to that of Efb-C from the Gram 
positive bacterium S. aureus, which also binds C3 and blocks C3 cleavage by the C3 
convertases 88. However, Candida Pra1 acts differently from S. aureus inhibitor SCIN which 
blocks complement activation by stabilizing C3 convertases 86. In addition, secreted Pra1 also 





































mediating cleavage of C3b into iC3b by Factor I (manuscript 1). Therefore, secreted Pra1 
forms a double-protective layer against complement attack in the surrounding of C. albicans. 
Furthermore, secreted Pra1 binds back to the surface of C. albicans hyphae, and functions as a 
surface protein to acquire human complement regulators and plasminogen to mediate 
complement evasion and tissue invasion. 
 
As a complement inhibitor, Pra1 also inhibits C5a generation. However, as Pra1 has already 
blocked complement activation at the level of C3, it is currently unclear whether the blockade 
of C5a release is a direct effect by inhibiting the assembly of the C5 convertase (C3bBbC3b or 
C4bC2bC3b), or an indirect effect due to the inhibition of C3 conversion. Independent of the 
exact mechanism, Candida Pra1 mediated inhibition of C3a- and C5a generation may prevent 
inflammatory effector functions, like recruitment of immune effector cells to the sites of 
infection 242,243. Thus, secreted Pra1, by inhibiting complement activation, builds up an anti-
inflammatory environment, which favors C. albicans survival. 
 
Soluble Pra1 by blocking C3 conversion inhibits C3b/iC3b mediated adhesion and 
phagocytosis of the yeast by human macrophages 
C3b or iC3b, when deposited onto the surface of a microbe, are efficiently recognized by 
complement receptors, i.e CR1 or CR3 which are expressed on the surface of human 
phagocytes, thus favoring phagocytosis and efficient removal of opsonized microbes 244. As a 
complement inhibitor, Pra1 by complexing C3 in solution, blocks C3 conversion, thereby 
inhibiting C3b/iC3b generation and deposition on the surface of C. albicans upon either AP or 
CP/LP activation (manuscript 2). Consequently, this inhibitory effect interferes with 
C3b/iC3b mediated adhesion and phagocytosis of the yeast by human macrophages and aids in 
the immune escape of the yeast from cellular immune responses. However, the inhibition of 
Pra1 on C3b/iC3b mediated adhesion and phagocytosis is only partial because multiple other 
receptors also play a role for recognition of C. albicans by macrophages, like Toll-like 
receptors and dectin-1 151,245,246. 
     
The biological function of Pra1 correlates with the concentration of native secreted Pra1 
Pra1 is secreted by C. albicans in a time dependent manner. Ten million yeast cells secrete 
ca. 5 µg of Pra1 within 24 h (manuscript 2). This concentration correlates with the biological 
effect observed for recombinant Pra1 (1~10 µg). However, during infection and tissue 







hyphal induction 247. This provides further evidence for the biological relevance of Pra1 in 
vivo. 
 
Taken together, C. albicans secretes a potent complement inhibitor Pra1, which in the direct 
surrounding of the pathogen, (i) complexes C3 in fluid phase, (ii) inhibits C3 cleavage by C3 
convertases of both the AP and the CP/LP, thereby blocking the release of the anaphylatoxins 
C3a and C5a, as well as C3b/iC3b surface deposition, (iii) by blocking C3 conversion, inhibits 
further complement progression and downstream effector function, such as anaphylotoxin C3a 
and C5a based inflammation, as well as C3b/iC3b mediated adhesion and phagocytosis of the 

















Figure 10. Secreted Candida Pra1 inhibits complement activation at level of C3. C. albicans secretes Pra1 
into solution. Upon the complement activation, soluble Pra1 (i) complexes the central complement component C3, 
inhibits C3 activation and cleavage by C3 convertases, (ii) inhibits C3a release and C3b/iC3b deposition at 
C. albicans surface, and (iii) blocks the further complement progression and downstream complement effector 
functions, such as anaphylotoxin C3a and C5a based inflammation and C3b/iC3b mediated phagocytosis of the 









































































Complement inhibitory effect of soluble Pra1 differs from Factor H binding 
Soluble Pra1 is a potent complement inhibitor that blocks complement activation at the level 
of C3. Pra1 also binds Factor H. Factor H, as an AP complement regulator, controls the action 
of C3 convertase of the AP, prevents C3 convertase formation and also dissociates a 
preformed convertase 248. Therefore, I defined whether Pra1 mediated blockade of 
complement activation is based on Factor H recruitment. It turns out that Pra1 blocks the lysis 
of sheep and rabbit erythrocytes, C3a release and also C3b/iC3b surface deposition also in 
∆Factor H-HS (manuscript 2). In addition, the inhibitory effect of Pra1 on CP/LP activation 
further proves that the blockade of C3 conversion is independent of Factor H binding as Factor 
H only controls the AP but not the CP/LP. Therefore, this new function of Pra1 mediated 
complement inactivation and Factor H recruitment are independent from each other.  
 
Function of Pra1 when bound to human cell surfaces 
 
Pra1 binds to human cells 
During the course of infection, C. albicans uses surface Pra1 to acquire Factor H, FHL-1 and 
C4BP as well as plasminogen to escape the first immune defense line, complement attack and 
to mediate the degradation of the extra-cellular matrices. However, facing the cellular 
response mainly mediated by human phagocytes (like neutrophils, macrophages and dendritic 
cells) and also non phagocytotic endothelial and epithelial cell barriers, C. albicans evolved 
ways to overcome it. 
 
For the first time, I show that Pra1 expression level is up-regulated at fungal surface upon co-
cultivation of C. albicans with human endothelial, epithelial cells and also monocytic cells 
(manuscript 3). This effect is consistent with the up-regulation of PRA1 transcription when C. 
albicans adheres to epithelial cells 236. This suggests that Pra1 plays a role in C. albicans 
interacting with human cells. Pra1, as a CR3 binding protein, binds to CR3 expressing human 
phagocytes, like U937 cells, THP-1 as well as neutrophils 235. Interestingly, Pra1 also binds to 
non-phagocytic endothelial and epithelial cells that lack CR3 on the surface with even higher 
intensity (manuscript 3). Thus, these data indicate that the existence of a novel Pra1 receptor 
on the surface of human epithelial and endothelial cells. However, this new receptor is still 









Surface Pra1 binds to human endothelial cells and mediates C. albicans adhesion and 
invasion 
Upon infection, C. albicans encounters different human cell types. Different cell types exert 
different effector functions against microbial invasion. For example, non-phagocytic 
endothelial and epithelial cells form physical barriers which C. albicans has to invade and 
overcome. Neutrophils or macrophages initiate a fast immune response upon infection, which 
C. albicans has to avoid or escape. Thus, pathogen and human cell interaction plays a complex 
and key role in the pathogenesis of microbial pathogens. 
 
Upon co-culture of C. albicans with HUVEC cells, C. albicans either adheres or invades to the 
human endothelial cells (manuscript 3), which is considered as a critical step for the 
pathogenic yeast to overcome endothelial cell barrier and disseminate into deeper tissue 
layers 210. Such cellular invasion of C. albicans has been demonstrated for porcine vascular 
explants 249, and also for brain microvascular endothelial cells 210,250,251,252. Here, I show that 
surface attached Pra1 induces both adhesion and invasion of C. albicans into human 
endothelial cells that lack CR3. This interaction is blocked by specific Pra1 anti-serum, 
showing that Pra1 acts as a bridging molecule that mediates C. albicans contact with human 
endothelial cells (Figure 11). Similar to Pra1, two other surface proteins of C. albicans, Als3 
and Hwp1 also induce fungal adhesion and invasion of host cells 182,253. In addition, this 
feature seems conserved for many microbial pathogens, e.g. S. pneumoniae, Toxoplasma 
gondii, Citrobacter freundii, Listeria monocytogenes and S. aureus which also control and 
stimulate their own invasion of human endothelial cells via surface expressed virulence 
factors 254-258. 
 
Secreted Pra1 binds to human phagocytes and blocks surface CR3 mediated recognition of 
human pathogens  
Following invading and crossing a physical barrier, C. albicans must find ways to escape the 
recognition and surveillance by the human phagocytic cells. C. albicans secretes Pra1 which 
bind to CR3 at the surface of human phagocytic cells, and addition of Pra1 to C. albicans and 
neutrophil interaction system increases fungal survival 235 , which suggests that Pra1 may act 
as a decoy to block CR3 receptor, and inhibit further CR3 mediated-interaction with the 
surface expressed Pra1, thereby blocking the interaction or phagocytosis of yeast cells by 








In addition to protecting C. albicans from cell recognition, Pra1 also acts as a general inhibitor 
to block the recognition of human pathogens by human cells. The pneumococcal PspC protein 
recruits complement regulator Factor H to the cell surface of the human pathogenic 
S. pneumoniae via SCRs8-11 and SCRs19-20 of Factor H. In addition, Factor H binds CR3. 
Therefore, Factor H functions as a bridging protein and mediates S. pneumoniae entry into the 
CR3 expressing PMNs. This interaction progresses via a two-step mechanism. The initial 
contact is mediated through the interaction of pneumococcal-bound Factor H with 
glycosaminoglycans on the surface of human cells, while pneumococcal uptake depends on 
integrins (like CR3) and host signaling molecules such as PI3K. As CR3 is involved in such 
interaction, Pra1, as a CR3 binding protein efficiently inhibits Factor H mediated interaction of 
pneumococcus with human PMNs via binding to CR3. Furthermore, secreted Pra1 by binding 
to CR3 could also affect the cell signaling pathways (manuscript 4).   
 
Taken together, Pra1 binds to phagocytic monocytes which express CR3 on the surface, and 
also binds to non-phagocytic human endothelial cells which lack CR3 on the surface via a 
novel receptor. Upon binding to human endothelial cells, surface expressed Pra1 mediates 
C. albicans adhesion and invasion to human endothelial cells. In addition, Pra1 acts an 
inhibitor that blocks the CR3 mediated recognition of pneumococcus by PMNs. Thus, secreted 
Pra1 may also act as a decoy to block CR3 on the surfaces of human phagocytes, thereby 
mediating the evasion of C. albicans from the cellular immune response. Consequently, 
C. albicans likely utilizes secreted Pra1 to form the third protective layer in the surrounding of 
the yeast cells, so that host phagocytes have no chance to come close to C. albicans 
(Figure 11). However, how C. albicans exactly controls and balances the usage of surface and 
soluble Pra1 for invading host epithelial and endothelial cell barriers and escaping the host 






























Figure 11. Pra1 interferes with C. albicans interaction with human cells. Surface Pra1 binds to human 
non-phagocytic, CR3 deficient endothelial cells via a novel unknown receptor. Upon binding, Pra1 mediates C. 
albicans adhesion and invasion to human endothelial cells. In addition, Pra1 acts an inhibitor that blocks the CR3 
mediated recognition of pneumococcus by PMNs. Thus, soluble Pra1, via binding to CR3, may act as a decoy, 




Surface expression and sequence variation of PRA1 in clinical C. albicans 
isolates 
Pra1 elicits a strong immune response in infected patients 259. In this work, Pra1 was defined 
as a multiple functional virulence factor which plays a key role in mediating C. albicans for an 
infection. In order to correlate the in-vitro test of recombinant Pra1 with in-vivo situation of 
the native Pra1, I compared Pra1 surface expression levels and sequence variation in clinical 
isolates derived from different infected patients to that in wild type C. albicans strain. Pra1 is 
expressed at the surface of all tested clinical isolates. Pra1 surface expression levels in clinical 
isolates are either higher than or comparable to that of the wild type SC5314 strain. Sequence 
analysis of the PRA1 gene from each clinical isolate shows that Pra1 is a relatively conserved 
gene and is not as polymorphic as other Factor H/C4BP binding proteins of pathogens, 
including CRASPs of Borrelia species 260 or M protein from S. pyogenes 261. In the 897-base-
pair-long protein coding region, sixteen nucleotides are changed in the tested clinical isolates. 
These exchanges, which occur either in homozygous or in heterozygous scenarios were 
observed with different frequencies. Most of these changes do not affect the protein sequence 




























Ser154Thr, as well as Asp225Glu. However, three modulations in the 5’-terminus of the PRA1 
affect the protein sequence. For example, both a polar, uncharged Asn- at position 25 and a 
non-polar Gly residue at position 105 are changed to negatively charged Asp residues. In 
addition, a non polar Ile residue at position 111 is changed to a polar, uncharged Ser residue. 
Interestingly, A73G exchange that affects the Pra1 protein sequence (Asn25Asp) is observed 
in all tested clinical isolates with the same homozygousity, in comparison with the standard 
Pra1 derived from the wild type strain SC5314 (manuscript 3). This exchange likely 
represents the most relevant site of the PRA1 gene for an infection.  
 
Conclusions-Pra1 is a multifunctional virulence factor which favors fungal 
survival at different sites 
Pra1 is a surface protein and also released by both Candida yeast cells and hyphae, and does 
also bind to human cells 235,262. The different locations allow Candida Pra1 to display different 
functions at distinct sites: (i) as a surface protein, Pra1 binds and acquires human complement 
regulators Factor H, FHL-1 and C4BP as well as plasminogen to the surface of the C. albicans. 
The attached human regulators display functional activities, control complement attack and 
mediate degradation of extra cellular matrixes, and consequently aid in Candida infection 
(manuscript 1); (ii) as a secreted protein, Pra1 complexes C3 in solution, blocks C3 cleavage 
by C3 convertases of both the AP and the CP/LP, inhibits further complement amplification 
and progression. Consequently Pra1 displays an anti-inflammatory effect by inhibiting the 
release of anaphylatoxins C3a and C5a and reduces attachment and uptake of yeast cells by 
human macrophages by blocking C3b/iC3b surface deposition (manuscript 2). Pra1, via 
binding Factor H, also enhances complement control mediated by complement regulator 
Factor H in fluid phase. In addition, secreted Pra1 binds back to the surface of C. albicans and 
functions as a surface protein; (iii) binding to the surface of host cells. Upon co-cultivation of 
C. albicans with human cells, Pra1 surface expression is highly up-regulated. Surface Pra1 by 
binding to human non-phagocytic, CR3 deficient endothelial via a novel receptor mediates C. 
albicans adhesion and invasion into the human endothelial cells (manuscript 3). In addition, 
secreted Pra1, via binding to surface integrin CR3, efficiently inhibits Factor H mediated 
interaction of pneumococcus with human epithelial and PMNs (manuscript 4) (Figure 12). 
Homozygous sequence variation of Asn25Asp likely represents a highly relevant site of the 








In summary, Pra1, as a multiple functional fungal complement inhibitor, apparently forms 
multiple protective layers which efficiently shield the human pathogenic yeast C. albicans 
from the humoral and cellular host immune responses. In addition, surface Pra1 acts as a 
bridging molecule to mediate C. albicans adhesion and invasion to non-phagocytic cell 
barriers. The multiple functions of Candida Pra1 provide an example for the multiplicity and 
complexity of the immune escape that are contributed by one single fungal virulence factor. A 
detailed understanding of these multiple roles of Pra1 allows to define new strategies to 

















Figure 12. The multiple functions of Candida Pra1. As a surface protein, Pra1 acquires Factor H, FHL-1, 
C4BP as well as plasminogen to the surface of C. albicans to mediate the complement evasion and degradation of 
extra-cellular matrices. Surface Pra1 can also act as a bridging molecule to mediate C. albicans adhesion and 
invasion to human non-phagocytes via binding to a novel receptor. As a secreted protein, Pra1, by complexing C3 
in solution, blocks C3 conversion, thereby inhibiting further complement progression and the effector functions. 
Secreted Pra1 binds to Factor H and enhances the complement control of Factor H in fluid phase. In addition, 
secreted Pra1 binds back to C. albicans surface and functions as a surface protein. When binding to the CR3 on 
the phagocyte surfaces, Pra1 blocks further recognition of pathogens by phagocytes via CR3, and may also affect 
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C. albicans is an opportunistic human pathogen that causes superficial, as well as life-
threatening infections in immuno-compromised patients. In order to establish an infection, C. 
albicans has developed multiple mechanisms to avoid host immune recognition and cross host 
tissue barriers. The aim of the work was to identify proteins from C. albicans that mediate 
immune, particularly complement evasion and to characterize these proteins on a molecular 
level. In this project, I identified and defined C. albicans Pra1 as a multifunctional virulence 
factor which mediates C. albicans for immune evasion and tissue invasion, thereby favoring 
fungal infection. Using the polyclonal Pra1 antis-serum, Pra1 was localized as a yeast surface 
protein and also secreted into the culture medium. Different locations specialize Pra1 different 
functions, (i) as a surface protein, Pra1 binds human complement regulators Factor H, FHL-1 
as well as plasminogen. In addition, Pra1 is the first fungal C4BP binding protein. The 
attached human regulators mediate complement evasion and degradation of extra-cellular 
matrices, and consequently favoring C. albicans invasion; (ii) as a secreted protein, Pra1 was 
identified as the first fungal complement inhibitor. Pra1 complexes C3 in solution, blocks C3 
cleavage by C3 convertases, thereby inhibiting further complement amplification and 
progression, and downstream complement effector functions, such as the inflammatory 
anaphylatoxins C3a and C5a generation, C3b/iC3b surface opsonization, as well as C3b/iC3b 
mediated adhesion and uptake of the yeast by human macrophages; and (iii) binding to the 
surface of human cells. Upon co-culture of C. albicans with human cells, Pra1 surface 
expression is up-regulated. For the first time, I show that Pra1 binds to human endothelial and 
epithelial cells in a CR3 independent manner via a novel receptor. Upon binding, surface Pra1 
functions as an invasin and mediates C. albicans for adhesion and invasion into human 
endothelial cells, thereby likely allowing this fungal pathogen to cross the tissue layers and 
cause invasive disease. In addition, Pra1 acts as an inhibitor that binds to CR3 and blocks CR3 
mediated recognition of pneumococcus by PMNs. 
 
In addition, I -for the first time-, identified Pra1 surface expression and sequence variation in 
clinical isolates derived from different infected patients. Pra1 is expressed at the surface of all 
tested clinical isolates. All tested isolates shows either higher or comparable Pra1 surface 
levels, as compared to the wild type C. albicans strain SC5314. Sequence analyses of the 
PRA1 gene identify a relevant nucleotide exchange (A73G) which also affects the amino acid 







factor that favors fungal survival at distinct sites. A detailed understanding of these multiple 
roles of Pra1 may allow to defining new strategies to interfere with and fight against 








































Der Mensch verfügt und nutzt ein komplexes und streng reguliertes Immunsystem das den 
Organismus vor infektiösen Erregern schützt. Allerdings haben pathogene Erreger im Lauf der 
Evolution gelernt die verschiedenen Immunbarrieren zu überwinden, sich in einem 
immunkompetenten Wirt auszubreiten und so Krankheiten zu verursachen. Candida albicans 
ist ein opportunistischer humanpathogener Erreger, der sowohl Oberfächeninfektionen aber 
auch systemische Erkrankungen verursachen kann. C. albicans verfügt über ein breites 
Arsenal von Mechanismen und Immunevasionsstrategien mit denen es dem Erreger gelingt die 
Immunabwehr des Menschen als dessen Wirt zu inhibieren. Ziel dieser Arbeit war es 
Virulenzfaktoren der humanpathogenen Hefe C. albicans zu identifizieren und diese zu 
charakterisieren. Dabei wurde Pra1 Protein (pH regulated antigen 1) der Hefe als 
multifunktioneller Virulenzfaktor identifiziert. Pra 1 steuerte die Immunevasion auf mehreren 
Ebenen, Pra1 agiert (i) als Komplement Inhibitor, (ii) als Faktor H, FHL1 und Plasminogen 
bindendes Protein, (iii) Pra1 bindet auch den Regulator des klassischen Weges C4BP und (iv) 
Pra 1 bindet an mindestens zwei Rezeptoren auf der Oberfläche von humane Makrophagen 
und Endothelzellen. Pra1 führt diese vielfältigen Funktionen in drei unterschiedlichen 
Kompartimenten aus: als Oberflächenprotein bindet Pra1 die Komplement Regulator Faktor 
H, FHL1, C4BP sowie Plasminogen und verhindert so die Opsonisierung der Oberfläche mit 
C3b bzw. erlaubt die Degradation von Extrazellulären Matrixproteinen. Als sezerniertes 
Protein wurde Candida Pra1 als erste Komplementinhibitor identifiziert,  der freies C3 bindet 
und so die weitere Aktivierung dieser zentralen Komplementkomponente verhindert. So kann 
die Hefe die Aktivierung des Komplement Kaskade, die Bildung von toxischen 
Aktivierungsprodukten sowie die Opsonierung und Phagozytose effizient blockieren. Auf der 
Oberfläche von human Zellen bindet Candida Pra1 an spezifische Rezeptoren. In dieser 
Arbeit wurde ein neuer Pra1 Rezeptor der auf humanen Endothel- und Epithelzellen 
exprimiert wird identifiziert. Pra1 ist ein wichtiger Virulenzfaktor der humanpathogenen Hefe 
Candida albicans, der vielfältigen Schritte der Immunevasion der humanpathogene Hefe 
kontrolliert und steuert und der an unterschiedlichen Kompartimenten agiert. Eine 
Inaktivierung dieses zentralen Virulenzfaktors bietet eine Möglichkeit die Infektionen mit der 
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